Gabriel Lopez-Berestein, M.D.

Peer-Reviewed Articles

1. Corvigno, S, Liu, Y, Bayraktar, E, Stur, E, Bayram, NN, Ahumada, AL, Nagaraju, S, Rodriguez-Aguayo, C, Chen, H, Vu, TC, Wen, Y, Liang, H, Zhao, L, Lee, S, Lopez Berestein, G, Sood, AK. Enhanced plant-derived vesicles for nucleotide delivery for cancer therapy. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 38582949.
2. Czopik AK, McNamee EN, Vaughn V, Huang X, Bang IH, Clark T, Wang Y, Ruan W, Nguyen T, Masterson JC, Tak E, Frank S, Collins CB, Li H, Rodriguez-Aguayo C, Lopez-Berestein G, Gerich ME, Furuta GT, Yuan X, Sood AK, de Zoeten EF, Eltzschig HK. HIF-2alpha-dependent induction of miR-29a restrains T(H)1 activity during T cell dependent colitis. Nat Commun 15(1):8042, 2024. e-Pub 2024. PMID: 39271652.
3. Joseph R, Dasari SK, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Kim MS, Corvigno S, Foster K, Hanjra P, Vu TC, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, Westin SN, Sood AK. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. Int J Mol Sci 25(2), 2024. e-Pub 2024. PMID: 38279277.
4. Bayraktar R, Pichler M, Kanlikilicer P, Ivan C, Bayraktar E, Kahraman N, Aslan B, Oguztuzun S, Ulasli M, Arslan A, Calin G, Lopez-Berestein G, Ozpolat B. Correction: MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget 14:908-909, 2023. e-Pub 2023. PMID: 37921671.
5. Chakraborty D, Gutierrez-Chakraborty E, Rodriguez-Aguayo C, Basagaoglu H, Lopez-Berestein G, Amero P. Discovering genetic biomarkers for targeted cancer therapeutics with eXplainable AI. bioRxiv, 2023. e-Pub 2023. PMID: 37546729.
6. Dragomir MP, Fuentes-Mattei E, Winkle M, Okubo K, Bayraktar R, Knutsen E, Qdaisat A, Chen M, Li Y, Shimizu M, Pang L, Liu K, Liu X, Anfossi S, Zhang H, Koch I, Tran AM, Mohapatra S, Ton A, Kaplan M, Anderson MW, Rothfuss SJ, Silasi R, Keshari RS, Ferracin M, Ivan C, Rodriguez-Aguayo C, Lopez-Berestein G, Georgescu C, Banerjee PP, Basar R, Li Z, Horst D, Vasilescu C, Bertilaccio MTS, Rezvani K, Lupu F, Yeung SC, Calin GA. Anti–miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune response. Journal of Clinical Investigation 133(14), 2023. e-Pub 2023. PMID: 37261908.
7. Liu Y, Ahumada AL, Bayraktar E, Schwartz P, Chowdhury M, Shi S, Sebastian MM, Khant H, de Val N, Bayram NN, Zhang G, Vu TC, Jie Z, Jennings NB, Rodriguez-Aguayo C, Swain J, Stur E, Mangala LS, Wu Y, Nagaraju S, Ermias B, Li C, Lopez-Berestein G, Braam J, Sood AK. Enhancing oral delivery of plant-derived vesicles for colitis. J Control Release 357:472-483, 2023. e-Pub 2023. PMID: 37031740.
8. LaFargue CJ, Amero P, Noh K, Mangala LS, Wen Y, Bayraktar E, Umamaheswaran S, Stur E, Dasari SK, Ivan C, Pradeep S, Yoo W, Lu C, Jennings NB, Vathipadiekal V, Hu W, Chelariu-Raicu A, Ku Z, Deng H, Xiong W, Choi HJ, Hu M, Kiyama T, Mao CA, Ali-Fehmi R, Birrer MJ, Liu J, Zhang N, Lopez-Berestein G, de Franciscis V, An Z, Sood AK. Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L. Nat Commun 14(1):2407, 2023. e-Pub 2023. PMID: 37100807.
9. Dasari SK, Joseph R, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, Westin SN, Sood AK. Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer. International journal of molecular sciences 24(4), 2023. e-Pub 2023. PMID: 36835335.
10. Jensen DM, Han P, Mangala LS, Lopez-Berestein G, Sood AK, Liu J, Kriegel AJ, Usa K, Widlansky ME, Liang M. Broad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications. Molecular Therapy 30(11):3462-3476, 2022. e-Pub 2022. PMID: 35965413.
11. Chaganty BKR, Qiu S, Lu Y, Lopez-Berestein G, Ozpolat B, Fan Z. Redirecting host preexisting influenza A virus immunity for cancer immunotherapy. Cancer Immunology, Immunotherapy 71(7):1611-1623, 2022. e-Pub 2022. PMID: 34731283.
12. Attia YM, Salama SA, Shouman SA, Ivan C, Elsayed AM, Amero P, Rodriguez-Aguayo C, Lopez-Berestein G. Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer. Pharmacological Reports 74(2):366-378, 2022. e-Pub 2022. PMID: 35000145.
13. Wen Y, Chelariu-Raicu A, Umamaheswaran S, Nick AM, Stur E, Hanjra P, Jiang D, Jennings NB, Chen X, Corvigno S, Glassman D, Lopez-Berestein G, Liu J, Hung MC, Sood AK. Endothelial p130cas confers resistance to anti-angiogenesis therapy. Cell Reports 38(4), 2022. e-Pub 2022. PMID: 35081345.
14. George J, Li Y, Kadamberi IP, Parashar D, Tsaih SW, Gupta P, Geethadevi A, Chen C, Ghosh C, Sun Y, Mittal S, Ramchandran R, Rui H, Lopez-Berestein G, Rodriguez-Aguayo C, Leone G, Rader JS, Sood AK, Dey M, Pradeep S, Chaluvally-Raghavan P. RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site. Cell Reports 37(5), 2021. e-Pub 2021. PMID: 34731628.
15. Ma S, Mangala LS, Hu W, Bayaktar E, Yokoi A, Hu W, Pradeep S, Lee S, Piehowski PD, Villar-Prados A, Wu SY, McGuire MH, Lara OD, Rodriguez-Aguayo C, LaFargue CJ, Jennings NB, Rodland KD, Liu T, Kundra V, Ram PT, Ramakrishnan S, Lopez-Berestein G, Coleman RL, Sood AK. CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Reports 36(7):109549, 2021. e-Pub 2021. PMID: 34407412.
16. Chakraborty D, Ivan C, Amero P, Khan M, Rodriguez-Aguayo C, Basagaoglu H, Lopez-Berestein G. Explainable Artificial Intelligence Reveals Novel Insight into Tumor Microenvironment Conditions Linked with Better Prognosis in Patients with Breast Cancer. Cancers 13(14), 2021. e-Pub 2021. PMID: 34298668.
17. Amero P, Lokesh GLR, Chaudhari RR, Cardenas-Zuniga R, Schubert T, Attia YM, Montalvo-Gonzalez E, Elsayed AM, Ivan C, Wang Z, Cristini V, Franciscis V, Zhang S, Volk DE, Mitra R, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein G. Conversion of RNA Aptamer into Modified DNA Aptamers Provides for Prolonged Stability and Enhanced Antitumor Activity. Journal of the American Chemical Society 143(20):7655-7670, 2021. e-Pub 2021. PMID: 33988982.
18. Gao C, Jin G, Forbes E, Mangala LS, Wang Y, Rodriguez-Aguayo C, Amero P, Bayraktar E, Yan Y, Lopez-Berestein G, Broaddus RR, Sood AK, Xue F, Zhang W. Inactivating mutations of the ik gene weaken ku80/ku70-mediated dna repair and sensitize endometrial cancer to chemotherapy. Cancers 13(10), 2021. e-Pub 2021. PMID: 34065218.
19. Gorur A, Bayraktar R, Ivan C, Mokhlis HA, Bayraktar E, Kahraman N, Karakas D, Karamil S, Kabil NN, Kanlikilicer P, Aslan B, Tamer L, Wang Z, Cristini V, Lopez-Berestein G, Calin G, Ozpolat B. ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer. Molecular Therapy Nucleic Acids 23:930-943, 2021. e-Pub 2021. PMID: 33614241.
20. Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Darcy KM, Conrads TP, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, Lopez-Berestein G, Lu KH, Coleman RL, Maxwell GL, Sood AK. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecologic oncology 160(3):777-785, 2021. e-Pub 2021. PMID: 33563487.
21. Ma S, McGuire MH, Mangala LS, Lee S, Stur E, Hu W, Bayraktar E, Villar-Prados A, Ivan C, Wu SY, Yokoi A, Dasari SK, Jennings NB, Liu J, Lopez-Berestein G, Ram P, Sood AK. Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. Cell Reports 34(6), 2021. e-Pub 2021. PMID: 33567287.
22. Elsayed AM, Bayraktar E, Amero P, Salama SA, Abdelaziz AH, Ismail RS, Zhang X, Ivan C, Sood AK, Lopez-Berestein G, Rodriguez-Aguayo C. Prkar1b-as2 long noncoding rna promotes tumorigenesis, survival, and chemoresistance via the pi3k/akt/mtor pathway. International journal of molecular sciences 22(4):1-25, 2021. e-Pub 2021. PMID: 33668685.
23. Noh K, Bach DH, Choi HJ, Kim MS, Wu SY, Pradeep S, Ivan C, Cho MS, Bayraktar E, Rodriguez-Aguayo C, Dasari SK, Stur E, Mangala LS, Lopez-Berestein G, Sood AK. The hidden role of paxillin. Oncogene 40(2):384-395, 2021. e-Pub 2021. PMID: 33149280.
24. Mangala LS, Rodriguez-Aguayo C, Bayraktar E, Jennings NB, Lopez-Berestein G, Sood AK. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol 2372:157-168, 2021. e-Pub 2021. PMID: 34417750.
25. Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC. Correction: Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res 26(18):5050, 2020. e-Pub 2020. PMID: 32934031.
26. Miyake TM, Pradeep S, Bayraktar E, Stur E, Handley KF, Wu SY, Rodriguez-Aguayo C, Lee JS, Lopez-Berestein G, Coleman RL, Sood AK. NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors. Mol Cancer Ther 19(8):1727-1735, 2020. e-Pub 2020. PMID: 32499298.
27. Lara OD, Bayraktar E, Amero P, Ma S, Ivan C, Hu W, Wang Y, Mangala LS, Dutta P, Bhattacharya P, Ashizawa AT, Lopez-Berestein G, Rodriguez-Aguayo C, Sood AK. Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. Oncotarget 11(29):2819-2833, 2020. e-Pub 2020. PMID: 32754300.
28. Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, Mangala LS, Taylor M, van den Beucken T, Koch E, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Wouters BG, Radovich M, Ivan M, Calin GA, Zhang W, Lopez-Berestein G, Sood AK. Author Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun 11(1):2867, 2020. e-Pub 2020. PMID: 32493919.
29. Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, Lopez-Berestein G, Sood AK, Ellis LM. Correction: Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene 39(23):4619, 2020. e-Pub 2020. PMID: 32366906.
30. Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan Y. Retraction Note: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature 582(7810):134, 2020. e-Pub 2020. PMID: 32483375.
31. Attia YM, Shouman SA, Salama SA, Ivan C, Elsayed AM, Amero P, Rodriguez-Aguayo C, Lopez-Berestein G. Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer. Int J Mol Sci 21(8), 2020. e-Pub 2020. PMID: 32340192.
32. El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal 68:109539, 2020. e-Pub 2020. PMID: 31935430.
33. Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Corrigendum to 'Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer' [EBioMedicine 38 (2018) 100-112]. EBioMedicine 52:102630, 2020. e-Pub 2020. PMID: 31972470.
34. Pichler M, Rodriguez-Aguayo C, Nam SY, Dragomir MP, Bayraktar R, Anfossi S, Knutsen E, Ivan C, Fuentes-Mattei E, Lee SK, Ling H, Catela Ivkovic T, Huang G, Huang L, Okugawa Y, Katayama H, Taguchi A, Bayraktar E, Bhattacharya R, Amero P, He WR, Tran AM, Vychytilova-Faltejskova P, Klec C, Bonilla DL, Zhang X, Kapitanovic S, Loncar B, Gafà R, Wang Z, Cristini V, Hanash SM, Bar-Eli M, Lanza G, Slaby O, Goel A, Rigoutsos I, Lopez-Berestein G, Calin GA. Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer. Gut. e-Pub 2020. PMID: 31988194.
35. Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, Liang M, Rader JS, Ramchandran R, You M, Sood AK, Kristensen VN, Mills GB, Pradeep S, Chaluvally-Raghavan P. miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. Cell Rep 29(13):4389-4406.e10, 2019. e-Pub 2019. PMID: 31875548.
36. Oncul S, Amero P, Rodriguez-Aguayo C, Calin GA, Sood AK, Lopez-Berestein G. Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum. RNA Biol:1-12. e-Pub 2019. PMID: 31847695.
37. Xu X, Wang Y, Mojumdar K, Zhou Z, Jeong KJ, Mangala LS, Yu S, Tsang YH, Rodriguez-Aguayo C, Lu Y, Lopez-Berestein G, Sood AK, Mills GB, Liang H. A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. J Clin Invest 129(12):5343-5356, 2019. e-Pub 2019. PMID: 31682236.
38. Yang H, Shu Z, Jiang Y, Mao W, Pang L, Redwood A, Jeter-Jones SL, Jennings NB, Ornelas A, Zhou J, Rodriguez-Aguayo C, Bartholomeusz G, Iles LR, Zacharias NM, Millward SW, Lopez-Berestein G, Le XF, Ahmed AA, Piwnica-Worms H, Sood AK, Bast RC, Lu Z. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. Clin Cancer Res 25(18):5702-5716, 2019. e-Pub 2019. PMID: 31391192.
39. Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Bayraktar R, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, Lacko AG, Sood AK. Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene 38(33):6095-6108, 2019. e-Pub 2019. PMID: 31289363.
40. Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. Corrigendum: FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 40(7):936, 2019. e-Pub 2019. PMID: 31063534.
41. Gunaratne PH, Pan Y, Rao AK, Lin C, Hernandez-Herrera A, Liang K, Rait AS, Venkatanarayan A, Benham AL, Rubab F, Kim SS, Rajapakshe K, Chan CK, Mangala LS, Lopez-Berestein G, Sood AK, Rowat AC, Coarfa C, Pirollo KF, Flores ER, Chang EH. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors. Cancer 125(14):2409-2422, 2019. e-Pub 2019. PMID: 31012964.
42. Amano H, Chaudhury A, Rodriguez-Aguayo C, Lu L, Akhanov V, Catic A, Popov YV, Verdin E, Johnson H, Stossi F, Sinclair DA, Nakamaru-Ogiso E, Lopez-Berestein G, Chang JT, Neilson JR, Meeker A, Finegold M, Baur JA, Sahin E. Telomere Dysfunction Induces Sirtuin Repression that Drives Telomere-Dependent Disease. Cell Metab 29(6):1274-1290.e9, 2019. e-Pub 2019. PMID: 30930169.
43. Azam SH, Porrello A, Harrison EB, Leslie PL, Liu X, Waugh TA, Belanger A, Mangala LS, Lopez-Berestein G, Wilson HL, McCann JV, Kim WY, Sood AK, Liu J, Dudley AC, Pecot CV. Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis. Oncogene 38(26):5191-5210, 2019. e-Pub 2019. PMID: 30918328.
44. Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan Y. Author Correction: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature 570(7761):E51, 2019. e-Pub 2019. PMID: 31127195.
45. Halder J, Kamat AA, Landen CN, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy. Clin Cancer Res 25(10):3194, 2019. e-Pub 2019. PMID: 31092618.
46. McGuire MH, Herbrich SM, Dasari SK, Wu SY, Wang Y, Rupaimoole R, Lopez-Berestein G, Baggerly KA, Sood AK. Pan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells. EBioMedicine 43:127-137, 2019. e-Pub 2019. PMID: 31056473.
47. Mokhlis HA, Bayraktar R, Kabil NN, Caner A, Kahraman N, Rodriguez-Aguayo C, Zambalde EP, Sheng J, Karagoz K, Kanlikilicer P, Abdel Aziz AAH, Abdelghany TM, Ashour AA, Wong S, Gatza ML, Calin GA, Lopez-Berestein G, Ozpolat B. The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers. Mol Ther Nucleic Acids 14:301-317, 2019. e-Pub 2019. PMID: 30654191.
48. Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. EBioMedicine 40:290-304, 2019. e-Pub 2019. PMID: 30655206.
49. Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Ming-Yang S, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK. Predicting novel therapies and targets: Regulation of Notch3 by the bromodomain protein BRD4. Mol Cancer Ther 18(2):421-436, 2019. e-Pub 2019. PMID: 30420565.
50. Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AK. PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Mol Cancer Ther 18(1):162-172, 2019. e-Pub 2019. PMID: 30305341.
51. Tekedereli I, Akar U, Alpay SN, Lopez-Berestein G, Ozpolat B. Autophagy is Required to Regulate Mitochondria Renewal, Cell Attachment, and All-trans-Retinoic Acid-Induced Differentiation in NB4 Acute Promyelocytic Leukemia Cells. J Environ Pathol Toxicol Oncol 38(1):13-20, 2019. e-Pub 2019. PMID: 30806286.
52. Gonzalez-Villasana V, Rashed MH, Gonzalez-Cantú Y, Bayraktar R, Menchaca-Arredondo JL, Vazquez-Guillen JM, Rodriguez-Padilla C, Lopez-Berestein G, Resendez-Perez D. Presence of Circulating miR-145, miR-155, and miR-382 in Exosomes Isolated from Serum of Breast Cancer Patients and Healthy Donors. Dis Markers 2019:6852917, 2019. e-Pub 2019. PMID: 30891102.
53. Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine 38:100-112, 2018. e-Pub 2018. PMID: 30487062.
54. González-González A, Muñoz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M, Jiménez G, Verma A, Ramírez A, Qian W, Chen W, Kozielski AJ, Elemento O, Martín-Salvago MD, Luque RJ, Rosa-Garrido C, Landeira D, Quintana-Romero M, Rosato RR, García MA, Ramirez-Tortosa CL, Kim H, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Lorente JA, Sánchez-Rovira P, Chang JC, Granados-Principal S. Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling. Clin Cancer Res 24(22):5697-5709, 2018. e-Pub 2018. PMID: 30012564.
55. Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC. Paclitaxel Sensitivity of Ovarian Cancer can be enhanced by knocking down Pairs of Kinases that regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res 24(20):5072-5084, 2018. e-Pub 2018. PMID: 30084832.
56. Inoue K, Deng Z, Chen Y, Giannopoulou E, Xu R, Gong S, Greenblatt MB, Mangala LS, Lopez-Berestein G, Kirsch DG, Sood AK, Zhao L, Zhao B. Bone protection by inhibition of microRNA-182. Nat Commun 9(1):4108, 2018. e-Pub 2018. PMID: 30291236.
57. Kabil N, Bayraktar R, Kahraman N, Mokhlis HA, Calin GA, Lopez-Berestein G, Ozpolat B. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer. Breast Cancer Res Treat 171(3):593-605, 2018. e-Pub 2018. PMID: 29971628.
58. Bayraktar R, Ivan C, Bayraktar E, Kanlikilicer P, Kabil NN, Kahraman N, Mokhlis HA, Karakas D, Rodriguez-Aguayo C, Arslan A, Sheng J, Wong S, Lopez-Berestein G, Calin GA, Ozpolat B. Dual suppressive effect of microRNA-34a on the FOXM1/eEF2-kinase axis regulates triple-negative breast cancer growth and invasion. Clin Cancer Res 24(17):4225-4241, 2018. e-Pub 2018. PMID: 29748184.
59. Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, S Eberlin L, Sood AK. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun 9(1):2923, 2018. e-Pub 2018. PMID: 30050129.
60. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest 128(7):3199, 2018. e-Pub 2018. PMID: 29809169.
61. Shahzad MMK, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK. Stress effects on FosB and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem 293(26):10041, 2018. e-Pub 2018. PMID: 29959278.
62. Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemmerle M, Gharpure KM, Rupaimoole R, Previs RA, Wu SY, Pradeep S, Xu X, Han HD, Zand B, Dalton HJ, Taylor M, Hu W, Bottsford-Miller J, Moreno-Smith M, Kang Y, Mangala LS, Rodriguez-Aguayo C, Sehgal V, Spaeth EL, Ram PT, Wong STC, Marini FC, Lopez-Berestein G, Cole SW, Lutgendorf SK, De Biasi M, Sood AK. Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction. Cancer Res 78(12):3233-3242, 2018. e-Pub 2018. PMID: 29661830.
63. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 3(11), 2018. e-Pub 2018. PMID: 29889660.
64. Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight 3(3):11, 2018. e-Pub 2018. PMID: 29889661.
65. Zhang P, Xiao Z, Wang S, Zhang M, Wei Y, Hang Q, Kim J, Yao F, Rodriguez-Aguayo C, Ton BN, Lee M, Wang Y, Zhou Z, Zeng L, Hu X, Lawhon SE, Siverly AN, Su X, Li J, Xie X, Cheng X, Liu LC, Chang HW, Chiang SF, Lopez-Berestein G, Sood AK, Chen J, You MJ, Sun SC, Liang H, Huang Y, Yang X, Sun D, Sun Y, Hung MC, Ma L. ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell Rep 23(3):823-837, 2018. e-Pub 2018. PMID: 29669287.
66. Mitamura T, Pradeep S, McGuire M, Wu SY, Ma S, Hatakeyama H, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, Chen X, Ivan C, Rodriguez-Aguayo C, Hu W, Lopez-Berestein G, Coleman RL, Sood AK. Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene 37(6):722-731, 2018. e-Pub 2018. PMID: 29059175.
67. Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AA. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun 9(1):476, 2018. e-Pub 2018. PMID: 29396402.
68. Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SC. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest 128(2):589-606, 2018. e-Pub 2018. PMID: 29251630.
69. Liu Y, Choi DS, Sheng J, Ensor JE, Liang DH, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A, Cong Y, Wong H, Qian W, Li Z, Granados-Principal S, Lopez-Berestein G, Landis MD, Rosato RR, Dave B, Wong S, Marchetti D, Sood AK, Chang JC. HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. Stem Cell Reports 10(1):212-227, 2018. e-Pub 2018. PMID: 29249663.
70. Lu Y, Hu Z, Mangala LS, Stine ZE, Hu X, Jiang D, Xiang Y, Zhang Y, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, DeMarzo AM, Sood AK, Zhang L, Dang CV. MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res 78(1):64-74, 2018. e-Pub 2018. PMID: 29180471.
71. Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, Mitra R, Gorenstein DG, Volk DE, de Franciscis V, Sood AK, Lopez-Berestein G. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Mol Ther Nucleic Acids 9:251-262, 2017. e-Pub 2017. PMID: 29246304.
72. Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, Nagaraja AS, Haemmerle M, Mak CSL, Chen X, Gharpure KM, Deng H, Xiong W, Kingsley CV, Liu J, Jennings N, Birrer MJ, Bouchard RR, Lopez-Berestein G, Coleman RL, An Z, Sood AK. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep 21(10):2785-2795, 2017. e-Pub 2017. PMID: 29212026.
73. Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, Hung MC, Marks JR, Gallick GE, Lopez-Berestein G, Flores ER, Sood AK, Huang S, Yu D, Yang L, Lin C. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest 127(12):4498-4515, 2017. e-Pub 2017. PMID: 29130936.
74. Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK. Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression. Clin Cancer Res 23(22):7034-7046, 2017. e-Pub 2017. PMID: 28855350.
75. Hu Q, Hisamatsu T, Haemmerle M, Cho MS, Pradeep S, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Wong STC, Sood AK, Afshar-Kharghan V. Role of Platelet-Derived Tgfβ1 in the Progression of Ovarian Cancer. Clin Cancer Res 23(18):5611-5621, 2017. e-Pub 2017. PMID: 28611202.
76. Rodriguez-Aguayo C, Monroig PDC, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, Mitra R, Sood AK, Calin GA, Lopez-Berestein G. Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discov 17029(3), 2017. e-Pub 2017.
77. Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AK. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun 8(310):310, 2017. e-Pub 2017. PMID: 28827520.
78. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 2(16), 2017. e-Pub 2017. PMID: 28814667.
79. Tseng JH, Bisogna M, Hoang LN, Olvera N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Levine DA, Jelinic P. miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. Sci Rep 7(1):3614, 2017. e-Pub 2017. PMID: 28620240.
80. Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA. Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clin Cancer Res 23(11):2891-2904, 2017. e-Pub 2017. PMID: 27903673.
81. Wagner MJ, Mitra R, McArthur MJ, Baze W, Barnhart K, Wu SY, Rodriguez-Aguayo C, Zhang X, Coleman RL, Lopez-Berestein G, Sood AK. Preclinical mammalian safety studies of EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA). Mol Cancer Ther 16(6):1114-1123, 2017. e-Pub 2017. PMID: 28265009.
82. Rigoutsos I, Lee SK, Nam SY, Anfossi S, Pasculli B, Pichler M, Jing Y, Rodriguez-Aguayo C, Telonis AG, Rossi S, Ivan C, Catela Ivkovic T, Fabris L, Clark PM, Ling H, Shimizu M, Redis RS, Shah MY, Zhang X, Okugawa Y, Jung EJ, Tsirigos A, Huang L, Ferdin J, Gafà R, Spizzo R, Nicoloso MS, Paranjape AN, Shariati M, Tiron A, Yeh JJ, Teruel-Montoya R, Xiao L, Melo SA, Menter D, Jiang ZQ, Flores ER, Negrini M, Goel A, Bar-Eli M, Mani SA, Liu CG, Lopez-Berestein G, Berindan-Neagoe I, Esteller M, Kopetz S, Lanza G, Calin GA. N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biol 18(1):98, 2017. e-Pub 2017. PMID: 28535802.
83. Court KA, Hatakeyama H, Wu SY, Lingegowda MS, Rodríguez-Aguayo C, López-Berestein G, Ju-Seog L, Rinaldi C, Juan EJ, Sood AK, Torres-Lugo M. HSP70 inhibition synergistically enhances the effects of magnetic fluid hyperthermia in ovarian cancer. Mol Cancer Ther 16(5):966-976, 2017. e-Pub 2017. PMID: 28223424.
84. Rabinowicz N, Mangala LS, Brown KR, Checa-Rodriguez C, Castiel A, Moskovich O, Zarfati G, Trakhtenbrot L, Levy-Barda A, Jiang D, Rodriguez-Aguayo C, Pradeep S, van Praag Y, Lopez-Berestein G, David A, Novikov I, Huertas P, Rottapel R, Sood AK, Izraeli S. Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer. Oncotarget 8(16):27380-27392, 2017. e-Pub 2017. PMID: 28423708.
85. Rashed MH, Kanlikilicer P, Rodriguez-Aguayo C, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Filant J, Silva A, Aslan B, Denizli M, Mitra R, Ozpolat B, Calin GA, Sood AK, Abd-Ellah MF, Helal GK, Berestein GL. Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget 8(12), 2017. e-Pub 2017. PMID: 28423620.
86. Bayraktar R, Pichler M, Kanlikilicer P, Ivan C, Bayraktar E, Kahraman N, Aslan B, Oguztuzun S, Ulasli M, Arslan A, Calin G, Lopez-Berestein G, Ozpolat B. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget 8(7):11641-11658, 2017. e-Pub 2017. PMID: 28036267.
87. Denizli M, Aslan B, Mangala LS, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK. Chitosan Nanoparticles for miRNA Delivery. Methods Mol Biol 1632(219):219-230, 2017. e-Pub 2017. PMID: 28730442.
88. Rodriguez-Aguayo C, Monroig PDC, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, Mitra R, Sood AK, Calin GA, Lopez-Berestein G. Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discov 3:17029, 2017. e-Pub 2017. PMID: 28904816.
89. Kanlikilicer P, Rashed MH, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C, Bayraktar E, Pichler M, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. Cancer Res. e-Pub 2016. PMID: 27742688.
90. Seviour EG, Sehgal V, Mishra D, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Lee JS, Sood AK, Kim MP, Mills GB, Ram PT. Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. Oncogene. e-Pub 2016. PMID: 27669434.
91. Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Karaminejadranjbar M, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Salah E, Abdul Azeez KR, Elkins JM, Campo L, Myers KA, Klotz D, Bivona S, Dhar S, Bast RC, Saya H, Choi HG, Gray NS, Fischer R, Kessler BM, Yau C, Sood AK, Motohara T, Knapp S, Ahmed AA. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell 30(2):273-89, 2016. e-Pub 2016. PMID: 27478041.
92. Harjes U, Bridges E, Gharpure KM, Roxanis I, Sheldon H, Miranda F, Mangala LS, Pradeep S, Lopez-Berestein G, Ahmed A, Fielding B, Sood AK, Harris AL. Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. Oncogene. e-Pub 2016. PMID: 27568980.
93. Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, Coarfa C, Gunaratne PH, Tsai KY, Flores ER. Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell 29(6):874-88, 2016. e-Pub 2016. PMID: 27300436.
94. Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Ram P, Liu J, Lu Y, Lopez-Berestein G, Calin GA, Sood AK, Mills GB. Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Rep 15(7):1493-504, 2016. e-Pub 2016. PMID: 27160903.
95. Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest 126(5):1885-1896, 2016. e-Pub 2016. PMID: 27064283.
96. Han HD, Cho YJ, Cho SK, Byeon Y, Jeon HN, Kim HS, Kim BG, Bae DS, Lopez-Berestein G, Sood AK, Shin BC, Park YM, Lee JW. Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma. Mol Cancer Ther 15(4):618-27, 2016. e-Pub 2016. PMID: 26861249.
97. Kang Y, Nagaraja AS, Armaiz-Pena GN, Dorniak PL, Hu W, Rupaimoole R, Liu T, Gharpure KM, Previs RA, Hansen JM, Rodriguez-Aguayo C, Ivan C, Ram PT, Sehgal V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer. Clin Cancer Res 22(7). e-Pub 2016. PMID: 26581245.
98. Rytelewski M, Maleki Vareki S, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD. Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget 7(15). e-Pub 2016. PMID: 26959114.
99. Dwivedi SK, Mustafi SB, Mangala LS, Jiang D, Pradeep S, Rodriguez-Aguayo C, Ling H, Ivan C, Mukherjee P, Calin GA, Lopez-Berestein G, Sood AK, Bhattacharya R. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget 7(12). e-Pub 2016. PMID: 26918603.
100. Redis RS, Vela LE, Lu W, Ferreira de Oliveira J, Ivan C, Rodriguez-Aguayo C, Adamoski D, Pasculli B, Taguchi A, Chen Y, Fernandez AF, Valledor L, Van Roosbroeck K, Chang S, Shah M, Kinnebrew G, Han L, Atlasi Y, Cheung LH, Huang GY, Monroig P, Ramirez MS, Catela Ivkovic T, Van L, Ling H, Gafà R, Kapitanovic S, Lanza G, Bankson JA, Huang P, Lai SY, Bast RC, Rosenblum MG, Radovich M, Ivan M, Bartholomeusz G, Liang H, Fraga MF, Widger WR, Hanash S, Berindan-Neagoe I, Lopez-Berestein G, Ambrosio AL, Gomes Dias SM, Calin GA. Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Mol Cell 61(4):520-34, 2016. e-Pub 2016. PMID: 26853146.
101. Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot CV, Sood AK, Mukherjee S, Gray JW, Mills GB, Ram PT. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene 35(6):801, 2016. e-Pub 2016. PMID: 26865225.
102. Rupaimoole R, Ivan C, Yang D, Gharpure KM, Wu SY, Pecot CV, Previs RA, Nagaraja AS, Armaiz-Pena GN, McGuire M, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Zhang W, Lopez-Berestein G, Calin GA, Sood AK. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene 35(33). e-Pub 2016. PMID: 26725326.
103. Lopez-Berestein, G, Seglen, P O, Klionsky O, D J, Abeliovich, H, Agostinis, P, Agrawal, D K, Aliev, G, Askew, D S, Baba, M, Baehrecke, E H, Bahr, B A, Ballabio, A, Bamber, B A, Bassham, D C, Bergamini, E, Bi, X, Biard-Piechaczyk, M, Blum, J S, Bredesen, D E, Brodsky, J L, Brumell, J H, Brunk, U T, Bursch, W, Camougrand, N, Cebollero, E, Cecconi, F, Chen, Y, Chin, L S, Choi, A, Chu, C T, Chung, J, Clarke, P G H, Clark, R S B, Clarke, S G, Clavé, C, Cleveland, J L, Codogno, P, Colombo, M I, Cotomontes, A, Cregg, J M, Cuervo, A M, Debnath, J, Demarchi, F, Dennis, P B, Dennis, P A, Deretic, V, Devenish, R J, Sano D, F, Dice, J F, DiFiglia, M, Dinesh-Kumar, S, Distelhorst, C W, Djavaheri-Mergny, M, Dorsey, F C, Dröge, W, Dron, M, Dunn, W A, Duszenko, M, Eissa, N T, Elazar, Z, Esclatine, A, Eskelinen, E L, Fésüs, L, Finley, K D, Fuentes, J M, Fueyo, J, Fujisaki, K, Galliot, B, Gao, F B, Gewirtz, D A, Gibson, S B, Gohla, A, Goldberg, A L, Gonzalez, R, González-Estévez, C, Gorski, S, Gottlieb, R A, Häussinger, D, He, Y W, Heidenreich, K, Hill, J A, Høyer-Hansen, M, Hu, X, Huang, W P, Iwasaki, A, Jäättelä, M, Jackson, W T, Jiang, X, Jin, S, Johansen, T, Jung, J U, Kadowaki, M, Kang, C, Kelekar, A, Kessel, D H, Kiel, J A K W, Hong, P K, Kimchi, A, Kinsella, T J, Kiselyov, K, Kitamoto, K, Knecht, E, Komatsu, M, Kominami, E, Kondo, S, Kovács, A L, Kroemer, G, Kuan, C Y, Kumar, R, Kundu, M, Landry, J, Laporte, M, Le, W, Lei, H Y, Lenardo, M J, Levine, B, Lieberman, A, Lim, K L, Lin, F C, Liou, W, Liu, L F, López-Otín, C, Lu, B, Macleod, K F, Malorni, W, Martinet, W, Matsuoka, K, Mautner, J, Meijer, A J, Meléndez, A, Michels, P, Miotto, G, Mistiaen, W P, Mizushima, N, Mograbi, B, Monastyrska, I, Moore, M N, Moreira, P I, Moriyasu, Y, Motyl, T, Münz, C, Murphy, L O. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356. Autophagy 12(2):443, 2016. e-Pub 2016.
104. Hatakeyama H, Wu SY, Mangala LS, Lopez-Berestein G, Sood AK. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol 1402:189-97, 2016. e-Pub 2016. PMID: 26721492.
105. Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, Yang D, Cooper LJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AK. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat Commun 7(15):11169, 2016. e-Pub 2016. PMID: 27041221.
106. Zhang X, Lopez-Berestein G, Sood AK, Calin GA. Profiling Long Noncoding RNA Expression Using Custom-Designed Microarray. Methods Mol Biol 1402:33-41, 2016. e-Pub 2016. PMID: 26721482.
107. Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK. Role of Increased n-acetylaspartate Levels in Cancer. J Natl Cancer Inst 108(6), 2016. e-Pub 2016. PMID: 26819345.
108. Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NM, Nagaraja AS, Gharpure KM, McGuire M, Sam N, Armaiz-Pena GN, Sadaoui NC, Rodriguez-Aguayo C, Calin GA, Drapkin RI, Kovacs J, Mills GB, Zhang W, Lopez-Berestein G, Bhattacharya PK, Sood AK. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Rep 13(11):2395-402, 2015. e-Pub 2015. PMID: 26686630.
109. Jung KH, Zhang J, Zhou C, Shen H, Gagea M, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Beretta L. Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. Hepatology 63(3). e-Pub 2015. PMID: 26599259.
110. Gaur S, Wen Y, Song JH, Parikh NU, Mangala LS, Blessing AM, Ivan C, Wu SY, Varkaris A, Shi Y, Lopez-Berestein G, Frigo DE, Sood AK, Gallick GE. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget 6(30):29161-77, 2015. e-Pub 2015. PMID: 26313360.
111. Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Peña GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell 28(5). e-Pub 2015. PMID: 26481148.
112. Park YY, Sohn BH, Johnson RL, Kang MH, Kim SB, Shim JJ, Mangala LS, Kim JH, Yoo JE, Rodriguez-Aguayo C, Pradeep S, Hwang JE, Jang HJ, Lee HS, Rupaimoole R, Lopez-Berestein G, Jeong W, Park IS, Park YN, Sood AK, Mills GB, Lee JS. YAP1 and TAZ Activates mTORC1 Pathway by Regulating Amino Acid Transporters in hepatocellular carcinoma. Hepatology 159(72). e-Pub 2015. PMID: 26389641.
113. Nagaraja AS, Dorniak PL, Sadaoui NC, Kang Y, Lin T, Armaiz-Pena G, Wu SY, Rupaimoole R, Allen JK, Gharpure KM, Pradeep S, Zand B, Previs RA, Hansen JM, Ivan C, Rodriguez-Aguayo C, Yang P, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene 35(18). e-Pub 2015. PMID: 26257064.
114. Timsah Z, Ahmed Z, Ivan C, Berrout J, Gagea M, Zhou Y, Pena GN, Hu X, Vallien C, Kingsley CV, Lu Y, Hancock JF, Liu J, Gladden AB, Mills GB, Lopez-Berestein G, Hung MC, Sood AK, Bogdanov M, Ladbury JE. Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene 35(17). e-Pub 2015. PMID: 26212011.
115. Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst 107(7), 2015. e-Pub 2015. PMID: 25995442.
116. Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, Wang H, Gol-Chambers A, Ozkayar O, Kanlikilicer P, Fuentes-Mattei E, Kahraman N, Pradeep S, Ozpolat B, Tucker S, Hung MC, Baggerly K, Bartholomeusz G, Calin G, Sood AK, Lopez-Berestein G. The ZNF304-integrin axis protects against anoikis in cancer. Nat Commun 6:7351, 2015. e-Pub 2015. PMID: 26081979.
117. Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature 520(7549). e-Pub 2015. PMID: 25901683.
118. Jin Y, Wang L, Qu S, Sheng X, Kristian A, Mælandsmo GM, Pällmann N, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood A, Lopez-Berestein G, Fazli L, Rennie P, Risberg B, Wæhre H, Danielsen HE, Ozpolat B, Saatcioglu F. STAMP2 increases oxidative stress and is critical for prostate cancer. EMBO Mol Med 7(3):315-31, 2015. e-Pub 2015. PMID: 25680860.
119. Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Jennings NB, Dorniak P, Hansen JM, Arevalo JM, Cole SW, Lutgendorf SK, Sood AK, Lopez-Berestein G. Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget 6(6):4266-73, 2015. e-Pub 2015. PMID: 25738355.
120. Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot C, Sood AK, Mukherjee S, Gray JW, Mills GB, Ram PT. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene 35(6). e-Pub 2015. PMID: 25639871.
121. Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, Sood AK, Mezzanzanica D, Liu J, Sun B, Zhang W. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol 235(1):25-36, 2015. e-Pub 2015. PMID: 25230372.
122. Zhang S, Lu Z, Mao W, Ahmed AA, Yang H, Zhou J, Jennings N, Rodriguez-Aguayo C, Lopez-Berestein G, Miranda R, Qiao W, Baladandayuthapani V, Li Z, Sood AK, Liu J, Le XF, Bast RC. CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. PLoS One 10(7):e0131833, 2015. e-Pub 2015. PMID: 26146988.
123. Shields BB, Pecot CV, Gao H, McMillan E, Potts M, Nagel C, Purinton S, Wang Y, Ivan C, Kim HS, Borkowski RJ, Khan S, Rodriguez-Aguayo C, Lopez-Berestein G, Lea J, Gazdar A, Baggerly KA, Sood AK, White MA. A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. Mol Syst Biol 11(12):842, 2015. e-Pub 2015. PMID: 26655797.
124. Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, Børresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GB. Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers. Cancer Cell 26(6):863-79, 2014. e-Pub 2014. PMID: 25490449.
125. Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AK. Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs. Mol Cancer Ther 13(12):2876-85, 2014. e-Pub 2014. PMID: 25281617.
126. Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Fuentes-Mattei E, Deng D, Hwang RF, Wang H, Ivan C, Garza RJ, Cohen E, Gao H, Armaiz-Pena GN, Del C Monroig-Bosque P, Philip B, Rashed MH, Aslan B, Erdogan MA, Gutierrez-Puente Y, Ozpolat B, Reuben JM, Sood AK, Logsdon C, Lopez-Berestein G. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound Paclitaxel in pancreatic ductal adenocarcinoma. Mol Cancer Ther 13(11):2583-94, 2014. e-Pub 2014. PMID: 25193509.
127. Zhaorigetu S, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein G, Walton BL. Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue. J Liposome Res 24(3):182-90, 2014. e-Pub 2014. PMID: 24443972.
128. Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan Y. miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature 512(7515):431-5, 2014. e-Pub 2014. PMID: 25043055.
129. Reusser NM, Dalton HJ, Pradeep S, Gonzalez-Villasana V, Jennings NB, Vasquez HG, Wen Y, Rupaimoole R, Nagaraja AS, Gharpure K, Miyake T, Huang J, Hu W, Lopez-Berestein G, Sood AK. Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer Biol Ther 15(8):1061-7, 2014. e-Pub 2014. PMID: 24841852.
130. Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 26(1):77-91, 2014. e-Pub 2014. PMID: 25026212.
131. Gharpure KM, Chu KS, Bowerman CJ, Miyake T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY, Luft JC, Napier ME, Lopez-Berestein G, DeSimone JM, Sood AK. Metronomic docetaxel in PRINT(R) nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Mol Cancer Ther 13(7):1750-7, 2014. e-Pub 2014. PMID: 24755199.
132. Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, Lutgendorf S, Sood AK. Focal adhesion kinase: An alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol Ther 15(7):919-29, 2014. e-Pub 2014. PMID: 24755674.
133. Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, Baggerly KA, Sood AK. MOLECULAR BIOMARKERS OF RESIDUAL DISEASE AFTER SURGICAL DEBULKING OF HIGH-GRADE SEROUS OVARIAN CANCER. Clin Cancer Res 20(12):3280-8, 2014. e-Pub 2014. PMID: 24756370.
134. Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK. Notch3 Pathway Alterations in Ovarian Cancer. Cancer Res 74(12):3282-93, 2014. e-Pub 2014. PMID: 24743243.
135. Wu SY, Lopez-Berestein G, Calin GA, Sood AK. RNAi therapies: drugging the undruggable. Sci Transl Med 6(240):240ps7, 2014. e-Pub 2014. PMID: 24920658.
136. Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Landen CN, Eblen ST. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis 35(5):1100-9, 2014. e-Pub 2014. PMID: 24379240.
137. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 7(2):488-500, 2014. e-Pub 2014. PMID: 24703838.
138. Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, Ivan C, Baggerly K, Lopez-Berestein G, Sood AK, Afshar-Kharghan V. Autocrine effects of tumor-derived complement. Cell Rep 6(6):1085-95, 2014. e-Pub 2014. PMID: 24613353.
139. Dalton HJ, Armaiz-Pena GN, Gonzalez-Villasana V, Lopez-Berestein G, Bar-Eli M, Sood AK. Monocyte Subpopulations in Angiogenesis. Cancer Res 5(5):1287-93, 2014. e-Pub 2014. PMID: 24556724.
140. Jain P, Kantarjian H, Estey E, Pierce S, Cortes J, Lopez-Berestein G, Ravandi F. Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data. Clin Lymphoma Myeloma Leuk 14(1):e47-9, 2014. e-Pub 2014. PMID: 24128595.
141. Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D, Sun Y, You MJ, Liu Y, Dean DC, Woodward WA, Liang H, Yang X, Lopez-Berestein G, Sood AK, Hu Y, Ang KK, Chen J, Ma L. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun 5:5671, 2014. e-Pub 2014. PMID: 25476932.
142. Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun 5:3459, 2014. e-Pub 2014. PMID: 24619206.
143. Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, Mangala LS, Taylor M, van den Beucken T, Koch E, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Wouters BG, Radovich M, Ivan M, Calin GA, Zhang W, Lopez-Berestein G, Sood AK. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun 5:5202, 2014. e-Pub 2014. PMID: 25351346.
144. Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun 5:5092, 2014. e-Pub 2014. PMID: 25277212.
145. Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, Tsukamoto T, Sood AK, Ram PT, Nagrath D. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol 10:728, 2014. e-Pub 2014. PMID: 24799285.
146. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest 123(12):5411, 2013. e-Pub 2013. PMID: 24292664.
147. Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GA. Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment. Cancer Discov 3(11):1302-15, 2013. e-Pub 2013. PMID: 24002999.
148. Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee JS, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AK. Tumour angiogenesis regulation by the miR-200 family. Nat Commun 4:2427, 2013. e-Pub 2013. PMID: 24018975.
149. Masiero M, Simões FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, Li JL, Patient R, Sood AK, Banham AH, Harris AL, Buffa FM. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell 24(2):229-41, 2013. e-Pub 2013. PMID: 23871637.
150. Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, Lu Y, Rodriguez-Aguayo C, Lopez-Berestein G, Mills GB, Sood AK, Lee JS. Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology 58(1):182-91, 2013. e-Pub 2013. PMID: 23389994.
151. Jin Y, Qu S, Tesikova M, Wang L, Kristian A, Mælandsmo GM, Kong H, Zhang T, Jerónimo C, Teixeira MR, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood AK, Lopez-Berestein G, Danielsen HE, Ozpolat B, Saatcioglu F. Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proc Natl Acad Sci U S A 110(28):E2572-81, 2013. e-Pub 2013. PMID: 23798432.
152. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest 123(5):2119-30, 2013. e-Pub 2013. PMID: 23585472.
153. Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G. Enhancing Chemotherapy Response with Sustained EphA2 Silencing Using Multistage Vector Delivery. Clin Cancer Res 19(7):1806-15, 2013. e-Pub 2013. PMID: 23386691.
154. Shahzad MM, Shin YH, Matsuo K, Lu C, Nishimura M, Shen DY, Kang Y, Hu W, Mora EM, Rodriguez-Aguayo C, Kapur A, Bottsford-Miller J, Lopez-Berestein G, Rajkovic A, Sood AK. Biological Significance of HORM-A Domain Containing Protein 1 (HORMAD1) in Epithelial Ovarian Carcinoma. Cancer Lett 330(2):123-9, 2013. e-Pub 2013. PMID: 22776561.
155. Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AK. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol 128(3):506-11, 2013. e-Pub 2013. PMID: 23200915.
156. Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, Liu J, Shmulevich I, Sood AK, Chen K, Zhang W. Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer. Cancer Cell 23(2):186-99, 2013. e-Pub 2013. PMID: 23410973.
157. Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer. Clin Cancer Res 19(4):809-20, 2013. e-Pub 2013. PMID: 23344261.
158. Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shazhad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK. Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun 4:1403, 2013. e-Pub 2013. PMID: 23360994.
159. Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CN. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Cancer Res 19(1):170-82, 2013. e-Pub 2013. PMID: 23147994.
160. Tekedereli I, Alpay SN, Akar U, Yuca E, Ayugo-Rodriguez C, Han HD, Sood AK, Lopez-Berestein G, Ozpolat B. Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast Cancer. Mol Ther Nucleic Acids 2:e121, 2013. e-Pub 2013. PMID: 24022053.
161. Armaiz-Pena, GN, Villarea GJ, Cruz A, Lin YG, Han LY, Allen JK, Nick AM, Stone RL, Mangala LS, Vivas-Mejia P, Wu Z, English R, Soman KV, Shazhad MMK, Deavers MT, Zien A, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Lopez GE, Gallick GE, Geest KD, Bar-Eli M, Lopez-Berestein G, Cole SW, Lutgendorf SK, Sood AK. Phosphorylation Src S17 is required for stress-induced cancer growth. Nature Comm 29(4):1403. e-Pub 2013.
162. Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, Visscher DW, Cliby W, Sood AK, Bhattacharya R, Mukherjee P. Cystathionine Beta-Synthase (CBS) Contributes to Advanced Ovarian Cancer Progression and Drug Resistance. PLoS One 8(11):e79167, 2013. e-Pub 2013. PMID: 24236104.
163. Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK. Correction: Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res 14(6):404. e-Pub 2012. PMID: 23259492.
164. Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 33(10):1843-53, 2012. e-Pub 2012. PMID: 22581827.
165. Shao LJ, Tekedereli I, Wang J, Yuca E, Tsang S, Sood AK, Lopez-Berestein G, Ozpolat B, Ittmann MM. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res 18(24):6648-6657. e-Pub 2012. PMID: 23052253.
166. Hussein YR, Sood AK, Bandyopadhyay S, Albashiti B, Semaan A, Nahleh Z, Roh J, Han HD, Lopez-Berestein G, Ali-Fehmi R. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Hum Pathol 43(10):1638-44, 2012. e-Pub 2012. PMID: 22436627.
167. Zhou HY, Chen SR, Byun HS, Chen H, Li L, Han HD, Lopez-Berestein G, Sood AK, Pan HL. N-Methyl-D-aspartate Receptor- and Calpain-mediated Proteolytic Cleavage of K+-Cl- Cotransporter-2 Disrupts Spinal Chloride Homeostasis in Neuropathic Pain. J Biol Chem 287(40):33853-64, 2012. e-Pub 2012. PMID: 22854961.
168. Ozpolat B, Akar U, Barria M, Lopez-Berestein G. PKCdelta regulates translation initiation through PKR and eIF2a in response to retinoic acid in acute myeloid leukemia cells. Leukemia Research & Therapy. e-Pub 2012. PMID: 23259068.
169. Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Research 14(6):404. e-Pub 2012. PMID: 22812534.
170. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Bánhegyi G, Bartholomew CR, Bassham DC, Bast RC, Batoko H, Bay BH, Beau I, Béchet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahová M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Cho. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8(4):445-544, 2012. e-Pub 2012. PMID: 22966490.
171. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupaimoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366(7):610-8, 2012. e-Pub 2012. PMID: 22335738.
172. Li L, Cao XH, Chen SR, Han HD, Lopez-Berestein G, Sood AK, Pan HL. Upregulation of Cavß3 subunit in primary sensory neurons increases voltage-gated Ca2+ channel activity and nociceptive input in neuropathic pain. J Biol Chem 287(8):6002-13, 2012. e-Pub 2012. PMID: 22187436.
173. Tekedereli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby KN, Ozpolat B. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One 7(7):e41171, 2012. e-Pub 2012. PMID: 22911754.
174. Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, Lu J, Tozzi F, Lopez-Berestein G, Vivas-Mejia P, Rashid A, Fleming JB, Abdalla EK, Curley SA, Vauthey JN, Sood AK, Yao JC, Ellis LM. Identification of Cancer Stem Cells in Human Gastrointestinal Carcinoid and Neuroendocrine Tumors. Gastroenterology 141(5), 2011. e-Pub 2011. PMID: 21806944.
175. Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein G, Sood AK. Silencing of p130Cas in Ovarian Carcinoma: A Novel Mechanism for Tumor Cell Death. J Natl Cancer Inst 103(21):1596-612, 2011. e-Pub 2011. PMID: 21957230.
176. Steg AD, Katre AA, Goodman BW, Han HD, Nick AM, Stone RL, Coleman RE, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CN. Targeting the Notch Ligand Jagged1 in Both Tumor Cells and Stroma in Ovarian Cancer. Clin Cancer Res 17(17), 2011. e-Pub 2011. PMID: 21753153.
177. Hu W, Lu C, Han HD, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora EM, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman R, Sood AK. Biological roles of the Delta family notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res 71(18), 2011. e-Pub 2011. PMID: 21795478.
178. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA, Medscape. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 8(8), 2011. e-Pub 2011. PMID: 21647195.
179. Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Silencing Survivin Splice Variant 2B Leads to Antitumor Activity in Taxane-Resistant Ovarian Cancer. Clin Cancer Res 17(11), 2011. e-Pub 2011. PMID: 21512144.
180. Moreno-Smith M, Lu C, Shahzad MM, Armaiz-Pena GN, Allen JK, Stonne RL, Mangala L, Han HD, Kim HS, Farley D, Lopez-Berestein G, Cole SW, Lutgendorf SK, Sood AK. Dopamine blocks stress mediated ovarian carcinoma growth. Clin Cancer Res 17(11), 2011. e-Pub 2011. PMID: 21531818.
181. Han HD, Mora EM, Roh JW, Nishimura M, Lee SJ, Stone RL, Bar-Eli M, Lopez-Berestein G, Sood AK. Chitosan hydrogel for localized gene silencing. Cancer Biol Ther 11(9):839-45, 2011. e-Pub 2011. PMID: 21358280.
182. Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, Mora EM, Lee JW, Stone RL, Pecot CV, Thanapprapasr D, Roh JW, Gaur P, Nair MP, Park YY, Sabnis N, Deavers MT, Lee JS, Ellis LM, Lopez-Berestein G, McConathy WJ, Prokai L, Lacko AG, Sood AK. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 13(4):309-19, 2011. e-Pub 2011. PMID: 21472135.
183. Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RK. Therapeutic Targeting of PELP1 Prevents Ovarian Cancer Growth and Metastasis. Clin Cancer Res 17(8):2250-9, 2011. e-Pub 2011. PMID: 21421858.
184. Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala L, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AK. Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res 17(7), 2011. e-Pub 2011. PMID: 21300758.
185. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11(1):59-67, 2011. e-Pub 2011. PMID: 21160526.
186. Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One 6(7):e21121, 2011. e-Pub 2011. PMID: 21754983.
187. Wang E, Bhattacharyya S, Szabolcs A, Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P, Sood AK, Bhattacharya R. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One 6(3):e17918, 2011. e-Pub 2011. PMID: 21445297.
188. Khakoo AY, Liu PP, Force T, Lopez-Berestein G, Jones LW, Schneider J, Hill J. Cardiotoxicity due to Cancer Therapy. Tex Heart Inst J 38(3):253-256, 2011. e-Pub 2011. PMID: 21720463.
189. Samuel S, Gaur P, Fan F, Xia L, Gray MJ, Dallas NA, Bose D, Rodriguez-Aguayo C, Lopez-Berestein G, Plowman G, Bagri A, Sood AK, Ellis LM. Neuropilin-2 Mediated ß-Catenin Signaling and Survival in Human Gastro-Intestinal Cancer Cell Lines. PLoS One 6(10):e23208, 2011. e-Pub 2011. PMID: 22028766.
190. Landen CN, Goodman BW, Katre AA, Steg AD, Nick AM, Stone R, Miller L, Vivas-Mejia PE, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer. Mol Cancer Ther 9(12), 2010. e-Pub 2010. PMID: 20889728.
191. Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK. Stress Effects on FosB- and Interleukin-8 (IL8)-driven Ovarian Cancer Growth and Metastasis. J Biol Chem 285(46):35462-70, 2010. e-Pub 2010. PMID: 20826776.
192. Feng S, Agoulnik IU, Truong A, Li Z, Creighton CJ, Kaftanovskaya EM, Pereira R, Han HD, Lopez-Berestein G, Klonisch T, Ittmann MM, Sood AK, Agoulnik AI. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer 17(4):1021-33, 2010. e-Pub 2010. PMID: 20861284.
193. Walton BL, Leja M, Vickers KC, Estevez-Fernandez M, Sanguino A, Wang E, Clubb FJ, Morrisett J, Lopez-Berestein G. Delivery of negatively charged liposomes into the atheromas of Watanabe heritable hyperlipidemic rabbits. Vasc Med 15(4):307-13, 2010. e-Pub 2010. PMID: 20724376.
194. Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther 9(8):2377-88, 2010. e-Pub 2010. PMID: 20682653.
195. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK. Regulation of Tumor Angiogenesis by EZH2. Cancer Cell 18(2):185-197, 2010. e-Pub 2010. PMID: 20708159.
196. Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Study Group AOC, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast RC. SIK2 Is a Centrosome Kinase Required for Bipolar Mitotic Spindle Formation that Provides a Potential Target for Therapy in Ovarian Cancer. Cancer Cell 18(2):109-121, 2010. e-Pub 2010. PMID: 20708153.
197. Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AK. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res 16(15):3910-22, 2010. e-Pub 2010. PMID: 20538762.
198. Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, Degeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 120(8), 2010. e-Pub 2010. PMID: 20389021.
199. Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari M. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 70(9):3687-96, 2010. e-Pub 2010. PMID: 20430760.
200. Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno NT, Hortobagyi GN, Arun B. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther 9(5):1180-7, 2010. e-Pub 2010. PMID: 20423989.
201. Alviar CL, Tellez A, Wallace-Bradley D, Lopez-Berestein G, Sanguino A, Schulz DG, Builes A, Ballantyne CM, Yang CY, Kaluza GL, Granada JF. Impact of adventitial neovascularisation on atherosclerotic plaque composition and vascular remodelling in a porcine model of coronary atherosclerosis. EuroIntervention 5(8):981-8, 2010. e-Pub 2010. PMID: 20542785.
202. Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein G. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res 16(1):184-94, 2010. e-Pub 2010. PMID: 20028751.
203. Cai YQ, Chen SR, Han HD, Sood AK, Lopez-Berestein G, Pan HL. Role of M(2), M(3), and M(4) Muscarinic Receptor Subtypes in the Spinal Cholinergic Control of Nociception Revealed Using siRNA in Rats. J Neurochem, 2009. e-Pub 2009. PMID: 19780895.
204. Vivas-Mejía PE, Ozpolat B, Chen X, Lopez-Berestein G. Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Int J Cancer 125(2):264-275, 2009. e-Pub 2009. PMID: 19408305.
205. Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther 8(11), 2009. e-Pub 2009. PMID: 19395869.
206. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res 15(11):3770-80, 2009. e-Pub 2009. PMID: 19470734.
207. Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, Zhu QS, Bornmann WG, McConkey DJ, Pollock RE, Lev DC. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res 15(10):3472-83, 2009. e-Pub 2009. PMID: 19417021.
208. Feng S, Agoulnik IU, Li Z, Han HD, Lopez-Berestein G, Sood A, Ittmann MM, Agoulnik AI. Relaxin/RXFP1 signaling in prostate cancer progression. Ann N Y Acad Sci 1160(1):379-80, 2009. e-Pub 2009. PMID: 19416223.
209. Zhang HM, Chen SR, Cai YQ, Richardson TE, Driver LC, Lopez-Berestein G, Pan HL. Signaling mechanisms mediating muscarinic enhancement of GABAergic synaptic transmission in the spinal cord. Neuroscience 158(4):1577-88, 2009. e-Pub 2009. PMID: 19110040.
210. Mangala LS, Han HD, Lopez-Berestein G, Sood AK. Liposomal siRNA for Ovarian Cancer. Methods Mol Biol 555(1):29-42, 2009. e-Pub 2009. PMID: 19495686.
211. Ramachandran V, Arumugam T, Langley R, Hwang RF, Vivas-Mejia P, Sood AK, Lopez-Berestein G, Logsdon CD. The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment. PLoS One 4(10):e7502, 2009. e-Pub 2009. PMID: 19847298.
212. Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, Lopez-Berestein G, Sood AK, Ellis LM. Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene 27(57):7192-200, 2008. e-Pub 2008. PMID: 18806828.
213. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer. N Engl J Med 359(25):2641-2650, 2008. e-Pub 2008. PMID: 19092150.
214. Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia PE, Sood AK, McConkey DJ, Logsdon CD. Nuclear Factor-{kappa}B p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells. Clin Cancer Res 14(24):8143-8151, 2008. e-Pub 2008. PMID: 19088029.
215. Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, Leslie MC, Vivas-Mejia PE, Lopez-Berestein G, Sood AK, Bar-Eli M. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res 68(21):9078-86, 2008. e-Pub 2008. PMID: 18974154.
216. Yang L, Hamilton SR, Sood A, Kuwai T, Ellis L, Sanguino A, Lopez-Berestein G, Boyd DD. The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression. Cancer Res 68(11):4321-30, 2008. e-Pub 2008. PMID: 18519692.
217. Akar U, Chaves-Reyez A, Barria M, Tari A, Sanguino A, Kondo Y, Kondo S, Arun B, Lopez-Berestein G, Ozpolat B. Silencing of Bcl-2 Expression by Small Interfering RNA Induces Autophagic Cell Death in MCF-7 Breast Cancer Cells. Autophagy 4(5):669-79, 2008. e-Pub 2008. PMID: 18424910.
218. Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-Berestein G, Sood AK, Aggarwal BB, Krishnan S, Gelovani JG, Mehta K. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res 14(8):2476-83, 2008. e-Pub 2008. PMID: 18413840.
219. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, Sood AK. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 100(5):359-72, 2008. e-Pub 2008. PMID: 18314475.
220. Gray MJ, Van Buren G, Dallas NA, Xia L, Wang X, Yang AD, Somcio RJ, Lin YG, Lim S, Fan F, Mangala LS, Arumugam T, Logsdon CD, Lopez-Berestein G, Sood AK, Ellis LM. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst 100(2):109-20, 2008. e-Pub 2008. PMID: 18182619.
221. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and Biological Significance of Tissue Transglutaminase in Ovarian Carcinoma. Cancer Res 68(14):5849-58, 2008. e-Pub 2008. PMID: 18632639.
222. Ozpolat B, Akar U, Zorrilla-Calancha I, Vivas-Mejia P, Acevedo-Alvarez M, Lopez-Berestein G. Death-Associated Protein 5 (DAP5/p97/NAT1) Contributes to Retinoic Acid-Induced Granulocytic Differentiation and Arsenic Trioxide-Induced Apoptosis in Acute Promyelocytic Leukemia. Apoptosis 13(7):915-28, 2008. e-Pub 2008. PMID: 18491231.
223. Fernández A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han HD, Mangala LS, Bankson JA, Gelovani J, Samarel A, Bornmann W, Sood AK, Lopez-Berestein G. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 117(12):4044-54, 2007. e-Pub 2007. PMID: 18060038.
224. Tari AM, Gutiérrez-Puente Y, Monaco G, Stephens C, Sun T, Rosenblum M, Belmont J, Arlinghaus R, Lopez-Berestein G. Liposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenografts. Int J Oncol 31(5):1243-50, 2007. e-Pub 2007. PMID: 17912453.
225. Landen CN, Lin YG, Armaiz Pena GN, Das PD, Arevalo JM, Kamat AA, Han LY, Jennings NB, Spannuth WA, Thaker PH, Lutgendorf SK, Savary CA, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res 67(21):10389-96, 2007. e-Pub 2007. PMID: 17974982.
226. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 67(22):10976-83, 2007. e-Pub 2007. PMID: 18006843.
227. Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Jennings N, Arevalo J, Lutgendorf SK, Gallick GE, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK. Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem 282(41):29919-26, 2007. e-Pub 2007. PMID: 17716980.
228. Ozpolat B, Akar U, Mehta K, Lopez-Berestein G. PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells. Autophagy 3(5):480-3, 2007. e-Pub 2007. PMID: 17507797.
229. Cheema SK, Gobin AS, Rhea R, Lopez-Berestein G, Newman RA, Mathur AB. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells. Int J Pharm 341(1-2):221-9, 2007. e-Pub 2007. PMID: 17499461.
230. Fernández A, Sanguino A, Peng Z, Crespo A, Ozturk E, Zhang X, Wang S, Bornmann W, Lopez-Berestein G. Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target. Cancer Res 67(9):4028-33, 2007. e-Pub 2007. PMID: 17483313.
231. Akar U, Ozpolat B, Mehta K, Fok J, Kondo Y, Lopez-Berestein G. Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol Cancer Res 5(3):241-9, 2007. e-Pub 2007. PMID: 17374730.
232. Akar, U, Ozpolat B, Mehta K, Fok J, Kondo Y, Lopez-Berestein G. PKC Delta and Tissue Transglutaminase are Novel Inhibitors of Autophagy in Pancreatic Cancer Cells. Mol Cancer Res 3(5):241-249, 2007. e-Pub 2007. PMID: 17507797.
233. Ozpolat B, Akar U, Steiner M, Zorrilla-Calancha I, Tirado-Gomez M, Colburn N, Danilendo M, Kornblau S, Lopez-Berestein G. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res 5(1):95-108, 2007. e-Pub 2007. PMID: 17259349.
234. Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK. Intraperitoneal Delivery of Liposomal siRNA for Therapy of Advanced Ovarian Cancer. Cancer Biol Ther 5(12):1708-13, 2006. e-Pub 2006. PMID: 17106249.
235. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12:939-44, 2006. e-Pub 2006. PMID: 16862152.
236. Halder J, Kamat AA, Landen CN, Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 12:4916-24, 2006. e-Pub 2006. PMID: 16914580.
237. Day CP, Rau KM, Qiu L, Liu CW, Kuo HP, Xie X, Lopez-Berestein G, Hortobagyi GN, Hung MC. Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Ther 13(7):706-19, 2006. e-Pub 2006. PMID: 16514421.
238. Tsimberidou AM, Tirado-Gomez M, Andreeff M, O'Brien S, Kantarjian H, Keating M, Lopez-Berestein G, Estey E. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leuk Lymphoma 47:1062-8, 2006. e-Pub 2006. PMID: 16840198.
239. Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, Hernandez IM, Gutierrez C, Lopez-Berestein G, Camacho LH. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 106(11):2437-44, 2006. e-Pub 2006. PMID: 16615096.
240. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23(35):8968-77, 2005. e-Pub 2005. PMID: 16204013.
241. Ozpolat B, Mehta K, Lopez-Berestein G. Regulation of a highly specific retinoic acid-4-hydroxylase (CYP26A1) enzyme and all-trans-retinoic acid metabolism in human intestinal, liver, endothelial, and acute promyelocytic leukemia cells. Leuk Lymphoma 46(10):1497-506, 2005. e-Pub 2005. PMID: 16194896.
242. Landen CN, Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65(15):6910-8, 2005. e-Pub 2005. PMID: 16061675.
243. Lu C, Perez-Soler R, Piperdi B, Walsh GL, Swisher SG, Smythe WR, Shin HJ, Ro JY, Feng L, Truong M, Yalamanchili A, Lopez-Berestein G, Hong WK, Khokhar AR, Shin DM. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol 23(15):3495-501, 2005. e-Pub 2005. PMID: 15908659.
244. Ng AW, Wasan KM, Lopez-Berestein G. Liposomal polyene antibiotics. Methods Enzymol 391:304-13, 2005. e-Pub 2005. PMID: 15721388.
245. Estey E, Koller C, Tsimberidou AM, O'Brien S, Beran M, Cortes J, Tirado-Gomez M, Lopez-Berestein G, Kantarjian H. Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. Blood 105(3):1366-7, 2005. e-Pub 2005. PMID: 15659618.
246. Harris MN, Ozpolat B, Abdi F, Gu S, Legler A, Mawuenyega KG, Tirado-Gomez M, Lopez-Berestein G, Chen X. Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia. Blood 104(5):1314-23, 2004. e-Pub 2004. PMID: 15142884.
247. Siwak DR, Tari AM, Lopez-Berestein G. Liposomal antisense oligonucleotides for cancer therapy. Methods Enzymol 387:241-53, 2004. e-Pub 2004. PMID: 15172168.
248. Ozpolat B, Tari AM, Mehta K, Lopez-Berestein G. Nuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells. Leuk Lymphoma 45(5):979-85, 2004. e-Pub 2004. PMID: 15291358.
249. Gutierrez-Puente Y, Tari AM, Ford RJ, Tamez-Guerra R, Mercado-Hernandez R, Santoyo-Stephano M, Lopez-Berestein G. Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line. Leuk Lymphoma 44(11):1979-85, 2003. e-Pub 2003. PMID: 14738153.
250. Ozpolat B, Lopez-Berestein G, Adamson P, Fu CJ, Williams AH. Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers. J Pharm Pharm Sci 6(2):292-301, 2003. e-Pub 2003. PMID: 12935441.
251. Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R, Lopez-Berestein G. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem 278(22):19995-20005, 2003. e-Pub 2003. PMID: 12644474.
252. Tari AM, Lim SJ, Hung MC, Esteva FJ, Lopez-Berestein G. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Oncogene 21(34):5224-32, 2002. e-Pub 2002. PMID: 12149644.
253. Zapata-Benavides P, Tuna M, Lopez-Berestein G, Tari AM. Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation. Biochem Biophys Res Commun 295(4):784-90, 2002. e-Pub 2002. PMID: 12127961.
254. Ozpolat B, Mehta K, Tari AM, Lopez-Berestein G. all-trans-Retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia. Am J Hematol 70(1):39-47, 2002. e-Pub 2002. PMID: 11994980.
255. Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 99(9):3461-4, 2002. e-Pub 2002. PMID: 11964319.
256. Rex JH, Walsh TJ, Nettleman M, Anaissie EJ, Bennett JE, Bow EJ, Carillo-Munoz AJ, Chavanet P, Cloud GA, Denning DW, de Pauw BE, Edwards Jr JE, Hiemenz JW, Kauffman CA, Lopez-Berestein G, Martino P, Sobel JD, Stevens DA, Sylvester R, Tollemar J, Viscoli C, Viviani MA, Wu T. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis 33(1):95-106, 2001. e-Pub 2001. PMID: 11389501.
257. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19(14):3422-33, 2001. e-Pub 2001. PMID: 11454891.
258. Tari AM, Mehta A, Lopez-Berestein G. Modulation of Akt activity by doxorubicin in breast cancer cells. J Chemother 13(3):334-6, 2001. e-Pub 2001. PMID: 11450894.
259. Yoo GH, Hung MC, Lopez-Berestein G, LaFollette S, Ensley JF, Carey M, Batson E, Reynolds TC, Murray JL. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 7(5):1237-45, 2001. e-Pub 2001. PMID: 11350889.
260. Douer D, Estey E, Santillana S, Lopez-Berestein G, Williams T. Treatment of newly diagnosed acute promyelocytic leukemia with intravenous liposomal-all-trans-retinoic-acid. Blood 97(1):73-80, 2001. e-Pub 2001.
261. Lim SJ, Lopez-Berestein G, Hung MC, Lupu R, Tari AM. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells. Oncogene 19(54):6271-6, 2000. e-Pub 2000. PMID: 11175341.
262. Diaz B, Lopez-Berestein G. A distinct element involved in lipopolysaccharide activation of the tumor necrosis factor-alpha promoter in monocytes. J Interferon Cytokine Res 20(8):741-8, 2000. e-Pub 2000. PMID: 10954918.
263. Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S, Lopez-Berestein G, Andreeff M. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 95(12):3929-38, 2000. e-Pub 2000. PMID: 10845930.
264. Tari AM, Lopez-Berestein G. Serum predominantly activates MAPK and akt kinases in EGFR- and ErbB2-over-expressing cells, respectively. Int J Cancer 86(2):295-7, 2000. e-Pub 2000. PMID: 10738260.
265. Ozpolat B, Zorrilla-Calancha I, Alvarez M, Gomez MT, Dimitrovsky E, Lopez-Berestein G. All-trans-Retinoic Acid and Arsenic Trioxide-induced Supression of Translational Initiation Involves DAP5/p97/NAT1 During Acute Myeloid Leukemia Cell Differentiation:Submitted/in Preparation, 2000. e-Pub 2000.
266. Pettaway C A, Song R, Williams S, Li E, Balbay M, Tari A M, Lopez-Berestein G, Jenster G, McConkey D J. Maintenance of growth and andrigen regulated gene expression subsequent to androgen ablation in LNCaP prostate carcioma cells overexpressing Bcl-2 is mediated in part via androgen signaling pathway:Submitted/in Preparation, 2000. e-Pub 2000.
267. Tari AM, Gutierrez-Puente Y, Stephen C, Rosenblum M, Lopez-Berestein G. Biodistribution and safety of liposome incorporated Grb2 antisense oligodeoxynucleotides . J. Mol. Med:in press, 2000. e-Pub 2000.
268. Tari AM, Kose GT, Lopez-Berestein G. Grb-2 activates MAPK Akt in Bcr-abl overexpressing cells, but only MAPK in EGFR overexpressing cells. . Eur. J. Biochem:in press, 2000. e-Pub 2000.
269. AntoniRibas, HCamacho L, Lopez-Berestein G, Comin-Anduix B, MReuben J, Seja E, Parker C, ABulanhagui C, Millham R, SEconomou J, Gualberto A, John AGlaspy DC, Gomez-Navarro J. Antitumoractivity and anti-self responses after CTLA-4 blockade in human subjects with the monoclonal antibody CP-675,206 JCO:in press, 2000. e-Pub 2000.
270. Gutierrez-Puente Y, Tari AM, Stephens C, Rosenblum M, Guerra RT, Lopez-Berestein G. Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. J Pharmacol Exp Ther 291(2):865-9, 1999. e-Pub 1999. PMID: 10525110.
271. Estey EH, Giles FJ, Kantarjian H, O'Brien S, Cortes J, Freireich EJ, Lopez-Berestein G, Keating M. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood 94(7):2230-5, 1999. e-Pub 1999. PMID: 10498593.
272. Swaminathan N, Lopez-Berestein G, Rudikoff S. Assessment of all-trans retinoic acid (ATRA) efficacy as a single agent in primary lymphoid neoplasia. Med Oncol 16(2):119-28, 1999. e-Pub 1999. PMID: 10456660.
273. Ueno NT, Xia W, Tucker SD, Zhang S, Lopez-Berestein G, Huang L, Hung MC. Issues in the development of gene therapy: preclinical experiments in E1A gene delivery. Oncol Rep 6(2):257-62, 1999. e-Pub 1999. PMID: 10022986.
274. Tari AM, Hung MC, Li K, Lopez-Berestein G. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene 18(6):1325-32, 1999. e-Pub 1999. PMID: 10022814.
275. Hortobagyi GN, Hung MC, Lopez-Berestein G. A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer. Hum Gene Ther 9(12):1775-98, 1998. e-Pub 1998. PMID: 9721088.
276. Tari AM, Stephens C, Rosenblum M, Lopez-Berestein G. Pharmacokinetics, tissue distribution and safety of P-ethoxy oligonucleotides incorporated in liposomes. J. Lip. Res 8(2):251-264, 1998. e-Pub 1998.
277. Tormo M, Tari AM, McDonnell TJ, Cabanillas F, Garcia-Conde J, Lopez-Berestein G. Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation. Leuk Lymphoma 30(3-4):367-79, 1998. e-Pub 1998. PMID: 9713967.
278. Beham A, Marin MC, Fernandez A, Herrmann J, Brisbay S, Tari AM, Lopez-Berestein G, Lozano G, Sarkiss M, McDonnell TJ. Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene 15(23):2767-72, 1997. e-Pub 1997. PMID: 9419967.
279. Adedoyin A, Bernardo JF, Swenson CE, Bolsack LE, Horwith G, DeWit S, Kelly E, Klasterksy J, Sculier JP, DeValeriola D, Anaissie E, Lopez-Berestein G, Llanos-Cuentas A, Boyle A, Branch RA. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother 41(10):2201-8, 1997. e-Pub 1997. PMID: 9333048.
280. Wallace TL, Paetznick V, Cossum PA, Lopez-Berestein G, Rex JH, Anaissie E. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob Agents Chemother 41(10):2238-43, 1997. e-Pub 1997. PMID: 9333054.
281. Tari A Lopez-Berestein G. Oligonucleotide therapy of hematological malignancies. J. Lip. Res 7(1):19-30, 1997. e-Pub 1997.
282. Sundaresan A, Claypool K, Mehta K, Lopez-Berestein G, Cabanillas F, Ford RJ, Jr. Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas. Cell Growth Differ 8(10):1071-82, 1997. e-Pub 1997. PMID: 9342185.
283. Tari AM, Arlinghaus R, Lopez-Berestein G. Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells. Biochem Biophys Res Commun 235(2):383-8, 1997. e-Pub 1997. PMID: 9199202.
284. Xing X, Liu V, Xia W, Stephens LC, Huang L, Lopez-Berestein G, Hung MC. Safety studies of the intraperitoneal injection of E1A--liposome complex in mice. Gene Ther 4(3):238-43, 1997. e-Pub 1997. PMID: 9135737.
285. Wasan KM Lopez-Berestein G. Alterations lipid transfer activity and plasma lipoprotein composition modify the pharmacological behaviour of hydrophobic drug agents. Rec. Res. Devel. Antimicrob. Agents Chemother 1:381-390, 1996. e-Pub 1996.
286. Tari AM, Andreeff M, Kleine HD, Lopez-Berestein G. Cellular uptake and localization of liposomal-methylphosphonate oligodeoxynucleotides. J Mol Med 74(10):623-8, 1996. e-Pub 1996. PMID: 8912183.
287. Estey E, Thall PF, Mehta K, Rosenblum M, Brewer T, Jr, Simmons V, Cabanillas F, Kurzrock R, Lopez-Berestein G. Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood 87(9):3650-4, 1996. e-Pub 1996. PMID: 8611689.
288. Tari A, Khodadadian M, Ellerson D, Deisseroth A, Lopez-Berestein G. Liposomal delivery of oligodeoxynucleotides. Leuk Lymphoma 21(1-2):93-7, 1996. e-Pub 1996. PMID: 8907275.
289. Vadiei K, Tucker SD, Lopez-Berestein G, Wasan KM. Nephroprotective mechanism(s) of pentoxifylline: reduction of erythrocyte-mediated vascular congestion and inhibition of nitric oxide release. Pharmacol Toxicol 78(3):174-80, 1996. e-Pub 1996. PMID: 8882351.
290. Tari A, Khodadadian M, Ellerson D, Deisseroth A, Lopez-Berestein G. Liposomal delivery of oligodeoxynucleotides. Leuk Lymphoma 21(1-2):93-7, 1996. e-Pub 1996. PMID: 8907275.
291. Wasan K Lopez-Berestein G. Modifying the therapeutic index of amphotericin B by its incorporation in negatively charged liposomes. J. Lip. Res 5(4):883-904, 1995. e-Pub 1995.
292. Wasan KM, Grossie VB, Jr, Lopez-Berestein G. Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion. Antimicrob Agents Chemother 38(9):2224-6, 1994. e-Pub 1994. PMID: 7811055.
293. Mehta K, Sadeghi T, McQueen T, Lopez-Berestein G. Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid. Leuk Res 18(8):587-96, 1994. e-Pub 1994. PMID: 8065160.
294. Wasan KM, Morton RE, Rosenblum MG, Lopez-Berestein G. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J Pharm Sci 83(7):1006-10, 1994. e-Pub 1994. PMID: 7965656.
295. Newell CL, Deisseroth AB, Lopez-Berestein G. Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNF-alpha gene. J Leukoc Biol 56(1):27-35, 1994. e-Pub 1994. PMID: 8027667.
296. Mehta RT, McQueen TJ, Keyhani A, Lopez-Berestein G. Phagocyte transport as mechanism for enhanced therapeutic activity of liposomal amphotericin B. Chemotherapy 40(4):256-64, 1994. e-Pub 1994. PMID: 8082414.
297. Tari AM, Tucker SD, Deisseroth A, Lopez-Berestein G. Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia. Blood 84(2):601-7, 1994. e-Pub 1994. PMID: 8025286.
298. Wasan KM, Hayman AC, Lopez-Berestein G. Determination of dimyristoylphosphatidylglycerol in human serum by liquid-liquid extraction and reversed-phase liquid chromatography. J Pharm Biomed Anal 12(6):851-4, 1994. e-Pub 1994. PMID: 7918789.
299. Wasan KM, Grossie VB, Jr, Lopez-Berestein G. Effects of intralipid infusion on rat serum lipoproteins. Lab Anim 28(2):138-42, 1994. e-Pub 1994. PMID: 8035564.
300. Gilbert BE, Wyde PR, Lopez-Berestein G, Wilson SZ. Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice. Antimicrob Agents Chemother 38(2):356-9, 1994. e-Pub 1994. PMID: 8192464.
301. Lopez-Berestein G, Rosenblum M, Sadeghi T, Mehta K. Pharmacokinetics, tissue distribution, and toxicology of tretinoin incorporated in liposomes. J. Lip. Res 4(1):689-700, 1994. e-Pub 1994.
302. Wasan KM, Rosenblum MG, Cheung L, Lopez-Berestein G. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother 38(2):223-7, 1994. e-Pub 1994. PMID: 8192447.
303. Constantino L, Mehta RT, Cruz ME, Lopez-Berestein G. Formulation, and toxicity of liposomes containing rifampicin. J. Lip. Res 3(2):275-301, 1993. e-Pub 1993.
304. Rios A, Rosenblum M, Crofoot G, Lenk RP, Hayman A, Lopez-Berestein G. Pharmacokinetics of liposomal nystatin in patients with human immunodeficiency virus infection. J Infect Dis 168(1):253-4, 1993. e-Pub 1993. PMID: 8515125.
305. Drach J, Lopez-Berestein G, McQueen T, Andreeff M, Mehta K. Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid. Cancer Res 53(9):2100-4, 1993. e-Pub 1993. PMID: 8481912.
306. Wasan KM, Brazeau GA, Keyhani A, Hayman AC, Lopez-Berestein G. Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob Agents Chemother 37(2):246-50, 1993. e-Pub 1993. PMID: 8452354.
307. Engelhard D, Eldor W, Polacheck I, Hardan I, Ben-Yehuda D, Amselem S, Salkin I F, Lopez-Berestein G, Sacks T, Rachmilewitz E A, Barenholz Y. Disseminated visceral fusariosis treated with amphotericin B-phospholipid complex. Leuk. Lymph 9:385-392, 1992. e-Pub 1992.
308. Walsh TJ, Lee JW, Melcher GP, Navarro E, Bacher J, Callender D, Reed KD, Wu T, Lopez-Berestein G, Pizzo PA. Experimental Trichosporon infection in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic mycosis. J Infect Dis 166(1):121-33, 1992. e-Pub 1992. PMID: 1535092.
309. Luke DR, Vadiei K, Lopez-Berestein G. Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 7(1):1-7, 1992. e-Pub 1992. PMID: 1316576.
310. Luke DR, Brunner LJ, Lopez-Berestein G, Yau JC. Pharmacokinetics of cyclosporine in bone marrow transplantation: longitudinal characterization of drug in lipoprotein fractions. J Pharm Sci 81(3):208-11, 1992. e-Pub 1992. PMID: 1640354.
311. Turpin JA, Blick M, Hester JP, Lopez-Berestein G. Tumor necrosis factor and c-fos expression in human peripheral-blood monocytes: expression is dependent on stage of in vitro differentiation. Nat Immun Cell Growth Regul 10(1):19-31, 1991. e-Pub 1991. PMID: 1905388.
312. Tucker SD, Sivaramakrishnan MR, Klostergaard J, Lopez-Berestein G. Independence of the pattern of early cytokine release from autoregulation by nitric oxide. J Leukoc Biol 50(5):509-16, 1991. e-Pub 1991. PMID: 1748844.
313. Vadiei K, Lopez-Berestein G, Perez-Soler R, Luke DR. Tissue distribution and in vivo immunosuppressive activity of liposomal cyclosporine. Drug Metab Dispos 19(6):1147-51, 1991. e-Pub 1991. PMID: 1687023.
314. Mehta RT, McQueen TJ, Keyhani A, Lopez-Berestein G. Liposomal hamycin: reduced toxicity and improved antifungal efficacy in vitro and in vivo. J Infect Dis 164(5):1003-6, 1991. e-Pub 1991. PMID: 1940451.
315. Yau JC, Brunner LJ, Lopez-Berestein G, LeMaistre CF, Luke DR. Therapeutic drug monitoring of cyclosporine-lipoprotein levels. Pharmacotherapy 11(4):291-5, 1991. e-Pub 1991. PMID: 1923909.
316. Wasan KM, Vadiei K, Luke DR, Keyhani A, White RA, McQueen TJ, Mehta R, Lopez-Berestein G. Antifungal activity of HWA-138 and amphotericin B in experimental systemic candidiasis. Antimicrob Agents Chemother 35(10):2046-8, 1991. e-Pub 1991. PMID: 1759826.
317. Seong D, Sims S, Johnson E, Lyding J, Lopez A, Garovoy M, Talpaz M, Kantarjian H, Lopez-Berestein G, Reading C, et al. Activation of class I HLA expression by TNF-alpha and gamma-interferon is mediated through protein kinase C-dependent pathway in CML cell lines. Br J Haematol 78(3):359-67, 1991. e-Pub 1991. PMID: 1908310.
318. Luke DR, Wasan KM, Verani RR, Brunner LJ, Berens KL, Vadiei K, Lopez-Berestein G. Attenuation of amphotericin-B nephrotoxicity in the candidiasis rat model. Nephron 59(1):139-44, 1991. e-Pub 1991. PMID: 1944727.
319. Turpin J, Mehta K, Blick M, Hester JP, Lopez-Berestein G. Effect of retinoids on the release and gene expression of tumor necrosis factor-alpha in human peripheral blood monocytes. J Leukoc Biol 48(5):444-50, 1990. e-Pub 1990. PMID: 2230595.
320. Lopez-Berestein G. Therapeutic activity of liposomal amphotericin B in systemic mycoses. J Lip Res 1(4):511-516, 1990. e-Pub 1990.
321. Howard OM, Talpaz M, Kantarjian H, Seong D, Wedrychowski A, Paslidis N, Hester J, Cork A, Turpin J, Lopez-Berestein G, et al. Interferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients. Blood 76(6):1117-30, 1990. e-Pub 1990. PMID: 2400807.
322. Langston JD, Wasan KM, Lopez-Berestein G, Verani RR, Luke DR. Evaluation of amphotericin B-cyclosporine interaction in the rat. Transplantation 50(3):506-10, 1990. e-Pub 1990. PMID: 2205957.
323. Luke DR, Wasan KM, McQueen TJ, Lopez-Berestein G. Enhancement of the treatment of experimental candidiasis with vascular decongestants. J Infect Dis 162(1):211-4, 1990. e-Pub 1990. PMID: 2355196.
324. Perez-Soler R, Lopez-Berestein G, Lautersztain J, al-Baker S, Francis K, Macias-Kiger D, Raber MN, Khokhar AR. Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II). Cancer Res 50(14):4254-9, 1990. e-Pub 1990. PMID: 2364384.
325. Seong D, Sims SS, Johnson E, Swan F, Lyding J, Lopez A, Talpaz M, Kantarjian H, Emerson S, Lopez-Berestein G, et al. Regulation of gene expression by tumor necrosis factor-alpha and interferon-gamma in chronic myelogenous leukemia. Trans Assoc Am Physicians 103:236-41, 1990. e-Pub 1990. PMID: 2132534.
326. Vadiei K, Lopez-Berestein G, Luke DR. Disposition and toxicity of amphotericin-B in the hyperlipidemic Zucker rat model. Int J Obes 14(6):465-72, 1990. e-Pub 1990. PMID: 2401582.
327. Wasan KM, Vadiei K, Lopez-Berestein G, Luke DR. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J Infect Dis 161(3):562-6, 1990. e-Pub 1990. PMID: 2313133.
328. Wedrychowski A, Seong D, Paslidis N, Johnson E, Howard OMZ, Sims S, Talpaz M, Kantarjian H, Hester J, Turpin J, Lopez-Berestein G, Gutterman J, Freireich EJ, Deisseroth A. Characterization of nuclear proteins which bind to interferon-inducible transcriptional enhancers in hematopoietic cells. J Biol Chem 265(35):21433-40, 1990. e-Pub 1990.
329. Kilbourn R, Lopez-Berestein G. Protease inhibitors block the macrophage-mediated inhibition of tumor cell mitochondrial respiration. J Immunol 144(3):1042-5, 1990. e-Pub 1990. PMID: 2295811.
330. Wasan KM, Vadiei K, Lopez-Berestein G, Verani RR, Luke DR. Pentoxifylline in amphotericin B toxicity rat model. Antimicrob Agents Chemother 34(2):241-4, 1990. e-Pub 1990. PMID: 2327772.
331. Lopez-Berestein G, Bodey GP, Fainstein V, Keating M, Frankel LS, Zeluff B, Gentry L, Mehta K. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med 149(11):2533-6, 1989. e-Pub 1989. PMID: 2818111.
332. Mehta RT, Hopfer RL, Juliano RL, Lopez-Berestein G. A comparison of in vitro toxicity and antifungal efficacy of membrane-active drugs after liposome encapsulation. Sel Cancer Ther 5(3):113-7, 1989. e-Pub 1989. PMID: 2479067.
333. Vadiei K, Perez-Soler R, Lopez-Berestein G, Luke DR. Pharmacokinetic and pharmacodynamic evaluation of liposomal-cyclosporine. Int J Pharma 57(2):125-31, 1989. e-Pub 1989.
334. Pontani DR, Sun D, Brown JW, Shahied SI, Plescia OJ, Schaffner CP, Lopez-Berestein G, Sarin PS. Inhibition of HIV replication by liposomal encapsulated amphotericin B. Antiviral Res 11(3):119-25, 1989. e-Pub 1989. PMID: 2472114.
335. Vadiei K, Lopez-Berestein G, Perez-Soler R, Luke D R. In vitro evaluation of liposomal cyclosporine. Int J Pharma 57(2):133-8, 1989. e-Pub 1989.
336. Midez JA, Hopfer RL, Lopez-Berestein G, Mehta RT. Effects of free and liposomal amphotericin B and gramicidin S alone and in combination on potassium leakage from human erythrocytes and Candida albicans. Antimicrob Agents Chemother 33(2):152-5, 1989. e-Pub 1989. PMID: 2470332.
337. Lopez-Berestein G, Turpin J, Hester J, Gschwind C, Reuben J. Effects of liposomal-amphotericin B on human peripheral blood monocytes and lymphocytes. J Lip Res 1:81-92, 1988. e-Pub 1988.
338. Murray JL, Mehta K, Lopez-Berestein G. Induction of adenosine deaminase and 5' nucleotidase activity in cultured human blood monocytes and monocytic leukemia (THP-1) cells by differentiating agents. J Leukoc Biol 44(3):205-11, 1988. e-Pub 1988. PMID: 2842422.
339. Lautersztain J, Perez-Soler R, Turpin J, Khokhar AR, Siddik ZH, Schmidt K, Lopez-Berestein G. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in mouse resident peritoneal macrophages, Kupffer cells, and hepatocytes. Cancer Res 48(5):1300-6, 1988. e-Pub 1988. PMID: 3342409.
340. Lopez-Berestein G. Liposomes as carriers of antifungal drugs. Ann N Y Acad Sci 544:590-7, 1988. e-Pub 1988. PMID: 3214094.
341. Hopfer RL, Mehta R, Lopez-Berestein G. Synergistic antifungal activity and reduced toxicity of liposomal amphotericin B combined with gramicidin S or NF. Antimicrob Agents Chemother 31(12):1978-81, 1987. e-Pub 1987. PMID: 2449867.
342. Perez-Soler R, Khokhar AR, Lopez-Berestein G. Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) encapsulated in multilamellar vesicles. Cancer Res 47(24 Pt 1):6462-6, 1987. e-Pub 1987. PMID: 3315188.
343. Mehta RT, Hopfer RL, Gunner LA, Juliano RL, Lopez-Berestein G. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother 31(21):1897-900, 1987. e-Pub 1987. PMID: 3439798.
344. Mehta RT, Hopfer RL, McQueen T, Juliano RL, Lopez-Berestein G. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother 31(12):1901-3, 1987. e-Pub 1987. PMID: 3439799.
345. Weber RS, Lopez-Berestein G. Treatment of invasive Aspergillus sinusitis with liposomal-amphotericin B. Laryngoscope 97(8):937-41, 1987. e-Pub 1987. PMID: 3613794.
346. Klostergaard J, Kilbourn RG, Foster WA, Lopez-Berestein G. Rapid, quantitative microassay for the monokine respiration inhibitory factor. J Immunol Methods 101(1):97-108, 1987. e-Pub 1987. PMID: 3112239.
347. Mehta K, Claringbold P, Lopez-Berestein G. Suppression of macrophage cytostatic activation by serum retinoids: a possible role for transglutaminase. J Immunol 138(11):3902-6, 1987. e-Pub 1987. PMID: 2884257.
348. Lee J, Mehta K, Blick MB, Gutterman JU, Lopez-Berestein G. Expression of c-fos, c-myb, and c-myc in human monocytes: correlation with monocytic differentiation. Blood 69(5):1542-5, 1987. e-Pub 1987. PMID: 3105625.
349. Metha K, Turpin J, Lopez-Berestein G. Induction of tissue transglutaminase in human peripheral blood monocytes by intracellular delivery of retinoids. J Leukoc Biol 41(4):341-8, 1987. e-Pub 1987. PMID: 2883247.
350. Eppstein DA, VanderPas MA, Fraser-Smith EB, Felgner PL, Jones G, Mehta R, Lopez-Berestein G. Liposome-encapsulated muramyl dipeptide analogue enhances non-specific host immunity. Int J Immunother 2(2):115-26, 1986. e-Pub 1986.
351. Perez-Soler R, Khokhar AR, Hacker MP, Lopez-Berestein G. Toxicity and antitumor activity of cis-bis-cyclopentenecarboxylato-1,2-diaminocyclohexane platinum(II) encapsulated in multilamellar vesicles. Cancer Res 46(12 Pt 1):6269-73, 1986. e-Pub 1986. PMID: 3779646.
352. Berman JD, Hanson WL, Chapman WL, Alving CR, Lopez-Berestein G. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother 30(6):847-51, 1986. e-Pub 1986. PMID: 3813512.
353. Perez-Soler R, Khokhar AR, Claringbold P, Kasi LP, Lopez-Berestein G. Effects on the monocyte-macrophage system and antitumor activity against L1210 leukemia of cis-bis-cyclopentenecarboxylato-trans-R,R-1,2-diaminocyclohexane -platinum (II) encapsulated in multilamellar vesicles. J Natl Cancer Inst 77(5):1137-43, 1986. e-Pub 1986. PMID: 2430132.
354. Lopez-Berestein G. Liposomal amphotericin B in the treatment of fungal infections. Ann Intern Med 105(1):130-1, 1986. e-Pub 1986. PMID: 3717785.
355. Mehta K, Claringbold P, Lopez-Berestein G. Amphotericin B inhibits the serum-induced expression of tissue transglutaminase in murine peritoneal macrophages. J Immunol 136(11):4206-12, 1986. e-Pub 1986. PMID: 2871108.
356. Klostergaard J, Foster WA, Hamilton DA, Turpin J, Lopez-Berestein G. Effector mechanisms of human monocyte-mediated tumor cytotoxicity in vitro: biochemical, functional, and serological characterization of cytotoxins produced by peripheral blood monocytes isolated by counterflow elutriation. Cancer Res 46(6):2871-5, 1986. e-Pub 1986. PMID: 3698012.
357. Turpin J, Hersh EM, Lopez-Berestein G. Characterization of small and large human peripheral blood monocytes: effects of in vitro maturation on hydrogen peroxide release and on the response to macrophage activators. J Immunol 136(11):4194-8, 1986. e-Pub 1986. PMID: 3084656.
358. Turpin J, Hester JP, Hersh EM, Lopez-Berestein G. Centrifugal elutriation as a method for isolation of large numbers of functionally intact human peripheral blood monocytes. J Clin Apher 3(2):111-8, 1986. e-Pub 1986. PMID: 3084457.
359. Sone S, Lopez-Berestein G, Fidler IJ. Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives. Cancer Immunol Immunother 21(2):93-9, 1986. e-Pub 1986. PMID: 3081250.
360. Nishioka K, Hopfer RL, el-Hagin T, Lopez-Berestein G. Prophylaxis of Candida albicans infection with tuftsin. J Antimicrob Chemother 17(3):361-3, 1986. e-Pub 1986. PMID: 3700295.
361. Mehta K, Lopez-Berestein G. Expression of tissue transglutaminase in cultured monocytic leukemia (THP-1) cells during differentiation. Cancer Res 46(3):1388-94, 1986. e-Pub 1986. PMID: 2867824.
362. Klostergaard J, Turpin J, Lopez-Berestein G. Effector mechanisms of human monocyte-mediated tumor cytotoxicity in vitro: parameters of induction of cytotoxins from peripheral blood monocytes isolated by counterflow elutriation. Cancer Res 46(2):662-9, 1986. e-Pub 1986. PMID: 3079667.
363. Lautersztain J, Perez-Soler R, Khokhar AR, Newman RA, Lopez-Berestein G. Pharmacokinetics and tissue distribution of liposome-encapsulated cis-bis-N-decyl-iminodiacetato-1,2-diaminocyclohexane-platinum (II). Cancer Chemother Pharmacol 18(2):93-7, 1986. e-Pub 1986. PMID: 3791565.
364. Anaissie E, Kantarjian H, Jones P, Barlogie B, Luna M, Lopez-Berestein G, Bodey GP, Fusarium. A newly recognized fungal pathogen in immunosuppressed patients. Cancer 57(11):2141-25, 1986. e-Pub 1986.
365. Mehta K, Claringbold P, Lopez-Berestein G. Amphotericin B inhibits the serum induced expression of tissue transglutaminase in murine peritoneal macrophages. J Immunol 136 (11):4206-12, 1986. e-Pub 1986.
366. Turpin J, Hersh EM, Lopez-Berestein G. Characterization of small and large human peripheral blood monocytes: Effects on in vitro maturation on hydrogen peroxide release and on the response to macrophage activators. J Immunol 136(11):4194-8, 1986. e-Pub 1986.
367. Saiki I, Sone S, Fogler WE, Kleinerman ES, Lopez-Berestein G, Fidler IJ. Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes. Cancer Res 45(12 Pt 1):6188-93, 1985. e-Pub 1985. PMID: 3933823.
368. Mehta RT, Lopez-Berestein G, Hopfer RL, Mehta K, White RA, Juliano RL. Prophylaxis of murine candidiasis via application of liposome-encapsulated amphotericin B and a muramyl dipeptide analog, alone and in combination. Antimicrob Agents Chemother 28(4):511-3, 1985. e-Pub 1985. PMID: 4073873.
369. Perez-Soler R, Lopez-Berestein G, Kasi LP, Cabanillas F, Jahns M, Glenn H, Hersh EM, Haynie T. Distribution of technetium-99m-labeled multilamellar liposomes in patients with Hodgkin's disease. J Nucl Med 26(7):743-9, 1985. e-Pub 1985. PMID: 3925093.
370. Perez-Soler R, Lopez-Berestein G, Cabanillas F, McLaughlin P, Hersh EM. Superoxide anion (O-2) production by peripheral blood monocytes in Hodgkin's disease and malignant lymphoma. J Clin Oncol 3(5):641-5, 1985. e-Pub 1985. PMID: 2987422.
371. Perez-Soler R, Lopez-Berestein G, Jahns M, Wright K, Kasi LP. Distribution of radiolabeled multilamellar liposomes injected intralymphatically and subcutaneously. Int J Nucl Med Biol 12(4):261-6, 1985. e-Pub 1985. PMID: 4086194.
372. Mehta K, Lopez-Berestein G, Moore WT, Davies PJ. Interferon-gamma requires serum retinoids to promote the expression of tissue transglutaminase in cultured human blood monocytes. J Immunol 134(4):2053-6, 1985. e-Pub 1985. PMID: 2857744.
373. Lopez-Berestein G, McQueen T, Mehta K. Protective effect of liposomal-amphotericin B against C. albicans infection in mice. Cancer Drug Deliv 2(3):183-9, 1985. e-Pub 1985. PMID: 4052931.
374. Sone S, Lopez-Berestein G, Fidler IJ. Kinetics and function of tumor cytotoxic factor(s) produced by human blood monocytes activated to the tumoricidal state. J Natl Cancer Inst 74(3):583-90, 1985. e-Pub 1985. PMID: 3856062.
375. Mehta RT, Mehta K, Lopez-Berestein G, Juliano RL. Effect of liposomal amphotericin B on murine macrophages and lymphocytes. Infect Immun 47(2):429-33, 1985. e-Pub 1985. PMID: 2578433.
376. Kilbourn RG, Klostergaard J, Lopez-Berestein G. Activated macrophages secrete a soluble factor that inhibits mitochondrial respiration of tumor cells. J Immunol 133(5):2577-81, 1984. e-Pub 1984. PMID: 6481163.
377. Lopez-Berestein G, Hopfer RL, Mehta R, Mehta K, Hersh EM, Juliano RL. Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis 150(2):278-83, 1984. e-Pub 1984. PMID: 6470530.
378. Lopez-Berestein G, Rosenblum MG, Mehta R. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv 1(3):199-205, 1984. e-Pub 1984. PMID: 6399857.
379. Lopez-Berestein G, Milas L, Hunter N, Mehta K, Hersh EM, Kurahara CG, Vandupas M, Eppstein DA. Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-O-stearoyl-N-acetylmuramyl-L-alpha-aminobutyryl-D-isoglutamine. Clin Exp Metastasis 2(2):127-37, 1984. e-Pub 1984. PMID: 6543694.
380. Kasi LP, Lopez-Berestein G, Mehta K, Rosenblum M, Glenn HJ, Haynie TP, Mavligit G, Hersh EM. Distribution and pharmacology of intravenous 99mTc-labeled multilamellar liposomes in rats and mice. Int J Nucl Med Biol 11(1):35-7, 1984. e-Pub 1984. PMID: 6735607.
381. Lopez-Berestein G, Hopfer RL, Mehta R, Mehta K, Hersh EM, Juliano RL. Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated amphotericin B. Antimicrob Agents Chemother 25(3):366-7, 1984. e-Pub 1984. PMID: 6721469.
382. Mehta K, Juliano RL, Lopez-Berestein G. Stimulation of macrophage protease secretion via liposomal delivery of muramyl dipeptide derivatives to intracellular sites. Immunology 51(3):517-27, 1984. e-Pub 1984. PMID: 6365745.
383. Hopfer RL, Mills K, Mehta R, Lopez-Berestein G, Fainstein V, Juliano RL. In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob Agents Chemother 25(3):387-9, 1984. e-Pub 1984. PMID: 6372684.
384. Mehta R, Lopez-Berestein G, Hopfer R, Mills K, Juliano RL. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta 770(2):230-4, 1984. e-Pub 1984. PMID: 6696909.
385. Kasi LP, Lopez-Berestein G, Mehta K, Juliano RL, Rosenblum M, Glenn H J, Haynie T P, Mavligit GM, Hersh EM. Distribution and pharmacology of 99m-Technetium labelled multilamellar liposomes. Int J Nucl Med 11(1):35-7, 1984. e-Pub 1984.
386. Lopez-Berestein G, Hopfer R, Mehta R, Mehta K, Juliano RL. Treatment of disseminated fungal infections in neutropenic mice with liposome-encapsulated amphotericin B. J Infect Dis 150(2):278-83, 1984. e-Pub 1984.
387. Lopez-Berestein G, Kasi L, Rosenblum MG, Haynie T, Jahns M, Glenn H, Mehta R, Mavligit GM, Hersh EM. Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer. Cancer Res 44(1):375-8, 1984. e-Pub 1984. PMID: 6317172.
388. Mehta R, Lopez-Berestein G, Hopfer R, Mehta K, Juliano R. Encapsulated Amphotericin B: Increased efficacy in the treatment of candidiasis. Biochem Biophys Acta 770:230-4, 1984. e-Pub 1984.
389. Juliano RL, Lopez-Berestein G, Mehta R, Hopfer R, Mehta K, Kasi L. Pharmacokinetic and therapeutic consequences of liposomal drug delivery: Fluorodeoxyuridine and Amphotericin B as examples. Biol Cell 47:39-46, 1983. e-Pub 1983.
390. Lopez-Berestein G, Cabanillas F, Osborne BM, Libshitz HI, Bodey GP. Study of the natural history of immunoblastic lymphadenopathy and atypical immunoproliferative disorders. Cancer Invest 4:293-9, 1983. e-Pub 1983. PMID: 6667410.
391. Lopez-Berestein G, Mehta R, Hopfer RL, Mills K, Kasi L, Mehta K, Fainstein V, Luna M, Hersh EM, Juliano R. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis 147(5):939-45, 1983. e-Pub 1983. PMID: 6842027.
392. Lopez-Berestein G, Reuben J, Hersh EM, Kilbourn R, Hester JP, Bielski M, Talpaz M, Mavligit GM. Comparative functional analysis of lymphocytes and monocytes from plateletapheresis. Transfusion 23(3):201-6, 1983. e-Pub 1983. PMID: 6679372.
393. Lopez-Berestein G, Mehta K, Mehta R, Juliano RL, Hersh EM. The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues. J Immunol 130(4):1500-2, 1983. e-Pub 1983. PMID: 6300230.
394. Lopez-Berestein G, Mehta R, Hopfer R, Mehta K, Hersh EM, Juliano R. Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Deliv 1(1):37-42, 1983. e-Pub 1983. PMID: 6544116.
395. Mehta K, Lopez-Berestein G, Hersh EM, Juliano RL. Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes. J Reticuloendothel Soc 32(2):155-64, 1982. e-Pub 1982. PMID: 7161762.

Invited Articles

1. Rupaimoole R, Han HD, Lopez-Berestein G, Sood AK. MicroRNA therapeutics: principles, expectations, and challenges. Chin J Cancer 30(6):368-70, 2011. e-Pub 2011.
2. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B. Targeting the prodeathand prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 6(3), 2010. e-Pub 2010.
3. Shahzad MM, Lopez-Berestein G, Sood AK. Novel strategies for reversing platinum resistance. Drug Resist Updat 12(6):148-52, 2009. e-Pub 2009.
4. Sanguino A, Lopez-Berestein G, Sood AK. Strategies for In Vivo siRNA Delivery in Cancer. Mini Rev Med Chem 3(3):248-55, 2008. e-Pub 2008. PMID: 18336345.
5. Gutierrez-Puente Y, Zapata-Benavides P, Tari AM, Lopez-Berestein G. Bcl-2-related antisense therapy. Semin Oncol 29(3):71-6, 2002. e-Pub 2002. PMID: 12138400.
6. Ozpolat B, Lopez-Berestein G. Liposomal-all-trans-retinoic acid in treatment of acute promyelocytic leukemia. Leuk Lymphoma 43(5):933-41, 2002. e-Pub 2002. PMID: 12148903.
7. Siwak DR, Tari AM, Lopez-Berestein G. The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin. Cancer Res., 8: 1172-1181, 2002. Clin Cancer Res 8(4):955-6, 2002. e-Pub 2002. PMID: 11948099.
8. Tari AM, Lopez-Berestein G. GRB2: a pivotal protein in signal transduction. Semin Oncol 28(5 Suppl 16):142-7, 2001. e-Pub 2001. PMID: 11706405.
9. Wasan K Lopez-Berestein G. Alterations in lipid transfer activity and plasma lipoprotein composition modify the pharmacologic behavior of hydrophobic drugs. Recent research developments in antimicrobial agents and chemotherapy, 2000. e-Pub 2000.
10. Lopez-Berestein G. Fungizone Roundtable: New applications of antifungals. . Amer. J. Med. Suppl, 2000. e-Pub 2000.
11. Wasan KM, Ng AWK, Lopez-Berestein G. Liposomal Polyenes. In Press. J Pharm Pharm Sci, 2000. e-Pub 2000.
12. Perez-Soler R, Lautersztain J, Khokhar A R, Lopez-Berestein G. Phase I clinical trial and pharmacology of L-NDDP. A preliminary report. J. Lip. Res, 2000. e-Pub 2000.
13. Lopez-Berestein G. Management of the immunocompromised patient: Impact of fungal infections. Rev. Infect. Dis, 2000. e-Pub 2000.
14. Lopez-Berestein G. Development of liposomal-amphotericin B. In Press. J. Lip. Res, 2000. e-Pub 2000.
15. Tari AM Lopez-Berestein G. Intracellular delivery and uptake of antisense oligonucleotides. Current Opinions in Investigational Drugs, 2000. e-Pub 2000.
16. Ozpolat, B, Tirado-Gomez, M, Lopez-Berestein, G. Liposomal-All-Trans-Retinoic-Acid in the treatment of Acute Promyelocytic Lekemia In Press. Curr Cancer Ther Rev, 2000. e-Pub 2000.
17. Tari SA M Lopez-Berestein G. Antisense oligonucoletides as inhibitors of Interleukin-1 activity. Allergy & Immunol. (Life Sci Adv) 14:53-56, 1995. e-Pub 1995.
18. Wasan KM, Lopez-Berestein G. The past, present, and future uses of liposomes in treating infectious diseases. Immunopharmacol Immunotoxicol 17(1):1-15, 1995. e-Pub 1995. PMID: 7759766.
19. Tormo M Lopez-Berestein G. Liposomas como transportadores de drogas para el cancer. Med. Interamericano 14(7):281-286, 1995. e-Pub 1995.
20. Mehta R Lopez-Berestein G. Liposomal-Nystatin. Drugs of the Future 19(8):724-730, 1994. e-Pub 1994.
21. Wasan K Lopez-Berestein G. Mechanisms of action of L-AmpB. J. Drug Target 2:373-380, 1994. e-Pub 1994.
22. Sutter M P Lopez-Berestein G. Biotechnology in Texas. Lyceum:16-22, 1994. e-Pub 1994.
23. Wasan K Lopez-Berestein G. Implications of hydrophobic drug interactions with plasma lipoproteins. Arch. Med. Res 24(4):395-401, 1993. e-Pub 1993.
24. Tari A Lopez-Berestein G. Antisense oligonucleotides and carriers for gene therapy. Cancer Bull 45(2):164-170, 1993. e-Pub 1993.
25. Deisseroth A, etal. Gene therapy: Chemoprotection, immunoenhancement, and modification of tumor cells. Cancer Bull 45(2):139-145, 1993. e-Pub 1993.
26. Perez-Soler R, Khokhar A R, Lautersztain J, Al-Baker S, Francis K, Macias-Kiger D, Lopez-Berestein G. Clinical development of liposomal-platinum. J. Lip. Res 50(14):4254-9, 1990. e-Pub 1990.
27. Lopez-Berestein G. Liposomes as carriers of antimicrobial agents. Antimicrob Agents Chemother 31(5):675-8, 1987. e-Pub 1987. PMID: 3300535.
28. Lopez-Berestein G. Liposomes as drug carriers for antifungals. Hospital Therapy 12(9):67-74, 1987. e-Pub 1987.
29. Lopez-Berestein G, Fainstein V, Hopfer R, etal. Liposomal-amphotericin B for the treatment of systemic fungal infections in patients with cancer. Year Book of Cancer:289-293, 1986. e-Pub 1986.
30. Mehta K, Lopez-Berestein G, etal. Interferon gamma requires retinoids to promote the expression of tissue transglutaminase in cultured human monocytes. Year Book of Cancer:276-277, 1986. e-Pub 1986.
31. Lopez-Berestein G. Prospects for the clinical application of liposomes as drug carriers. Cancer Bulletin 37(4):203-206, 1985. e-Pub 1985.
32. Mehta R, Lopez-Berestein G, Hopfer R, etal. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Year Book of Cancer:257-261, 1985. e-Pub 1985.
33. Lopez-Berestein G Kilbourn RG. Mononuclear phagocyte system cytotoxins. A review. Natl. Immunol. Cell Diff 4:78-89, 1985. e-Pub 1985.
34. Lopez-Berestein G, Milas L, Hunter N, etal. Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-0-stearoyl-MDP. Year Book of Cancer:25, 1985. e-Pub 1985.
35. Juliano RL, Lopez-Berestein G, Hopfer R, Mehta R, Mehta K, Mills K. Selective toxicity and enhanced therapeutic index of liposomal polyene antibiotics in systemic fungal infections. Ann N Y Acad Sci 446:390-402, 1985. e-Pub 1985. PMID: 3860162.
36. Juliano RL Lopez-Berestein G. New lives for old drugs. Trends Pharm. Sci 6(7):164-168, 1985. e-Pub 1985.
37. Lopez-Berestein G, Mehta R, Hopfer R, etal. Treatment and prophylaxis of disseminated infection due to C. albicans in mice with liposome-encapsulated amphotericin B. Year Book of Cancer:306-307, 1984. e-Pub 1984.

Other Articles

1. Rodriguez-Aguayo C, Del C Monroig P, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, Mitra R, Sood AK, Calin GA, Lopez-Berestein G Author Correction. Cell Discovery 9(1):111, 2023. PMID: 37940695.
2. Martinez-Castillo M, M Elsayed A, López-Berestein G, Amero P, Rodríguez-Aguayo C An Overview of the Immune Modulatory Properties of Long Non-Coding RNAs and Their Potential Use as Therapeutic Targets in Cancer. Non-coding RNA 9(6), 2023. PMID: 37987366.
3. Szymanowski W, Szymanowska A, Bielawska A, Lopez-Berestein G, Rodriguez-Aguayo C, Amero P Aptamers as Potential Therapeutic Tools for Ovarian Cancer. Cancers 15(21), 2023. PMID: 37958473.
4. Szymanowska, A, Rodriguez-Aguayo, C, Lopez Berestein, G, Amero, P Non-Coding RNAs. Non-coding RNA 9(5), 2023. PMID: 37736898.
5. Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, Amero P, Rodriguez-Aguayo C Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach. Non-coding RNA 9(2), 2023. PMID: 37104009.
6. Wen Y, Chelariu-Raicu A, Umamaheswaran S, Nick AM, Stur E, Hanjra P, Jiang D, Jennings NB, Chen X, Corvigno S, Glassman D, Lopez-Berestein G, Liu J, Hung MC, Sood AK Erratum. Cell Reports 42(3), 2023. PMID: 37274180.
7. George J, Li Y, Kadamberi IP, Parashar D, Tsaih SW, Gupta P, Geethadevi A, Chen C, Ghosh C, Sun Y, Mittal S, Ramchandran R, Rui H, Lopez-Berestein G, Rodriguez-Aguayo C, Leone G, Rader JS, Sood AK, Dey M, Pradeep S, Chaluvally-Raghavan P Erratum. Cell Reports 42(3), 2023. PMID: 36884347.
8. Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Carrami EM, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AA Author Correction. Nature communications 13(1), 2022. PMID: 35688808.
9. Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G Corrigendum to "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis" [EBioMedicine 40 (2019) 290-304]. EBioMedicine 83:104194, 2022. PMID: 35914489.
10. Wen Y, Chelariu-Raicu A, Umamaheswaran S, Nick AM, Stur E, Hanjra P, Jiang D, Jennings NB, Chen X, Corvigno S, Glassman D, Lopez-Berestein G, Liu J, Hung MC, Sood AK Erratum. Cell Reports 39(12):110999, 2022. PMID: 35732127.
11. El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G CORRIGENDUM. Cellular Signalling 89:110147, 2022. PMID: 34772589.
12. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK Author Correction. Nat Med 27(12):2246, 2021. PMID: 34799731.
13. Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X Author Correction. Nature 597(7875):E6, 2021. PMID: 34433970.
14. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MMK, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK Erratum. Clinical Cancer Research 27(15):4454, 2021. PMID: 34341059.
15. Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MMK, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AK Erratum. Clinical Cancer Research 27(15):4452, 2021. PMID: 34341057.
16. Moreno-Smith, M, Lu, C, Shahzad, MM, Armaiz Pena, GN, Allen, J, Stone, RL, Mangala, LS, Han, HD, Kim, HS, Farley, DM, Lopez Berestein, G, Cole, SW, Lutgendorf, SK, Sood, AK Erratum. Clinical Cancer Research 27(15):4451, 2021. PMID: 34341056.
17. Han HD, Mangala LS, Lee JW, Shahzad MMK, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AK Erratum. Clinical Cancer Research 27(15):4453, 2021. PMID: 34341058.
18. Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK Erratum. JCI Insight 6(7), 2021. PMID: 33793423.
19. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK Erratum. JCI Insight 6(7), 2021. PMID: 33793425.
20. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK Erratum. J Clin Invest 131(7), 2021. PMID: 33792569.
21. Amero P, Khatua S, Rodriguez-Aguayo C, Lopez-Berestein G Aptamers: Novel Therapeutics and Potential Role in Neuro-Oncology. Cancers (Basel) 12(10), 2020. PMID: 33050158.
22. Elsayed AM, Amero P, Salama SA, Abdelaziz AH, Lopez-Berestein G, Rodriguez-Aguayo C Back to the Future: Rethinking the Great Potential of lncRNAS for Optimizing Chemotherapeutic Response in Ovarian Cancer. Cancers (Basel) 12(9), 2020. PMID: 32854207.
23. Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev 37(1):107-124, 2018. PMID: 29243000.
24. Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GA microRNA Therapeutics in Cancer - An Emerging Concept. EBioMedicine 12:34-42, 2016. PMID: 27720213.
25. Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov 6(3):235-46, 2016. PMID: 26865249.
26. Gharpure KM, Wu SY, Li C, Lopez-Berestein G, Sood AK Nanotechnology: Future of Oncotherapy. Clin Cancer Res 21(14):3121-30, 2015. PMID: 26180057.
27. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 87:108-19, 2015. PMID: 25666164.
28. Ozpolat B, Sood AK, Lopez-Berestein G Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev 66C:110-116, 2014. PMID: 24384374.
29. Ozpolat B, Sood AK, Lopez-Berestein G Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med 267(1):44-53, 2010. PMID: 20059643.
30. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, Bamber BA, Bassham DC, Bergamini E, Bi X, Biard-Piechaczyk M, Blum JS, Bredesen DE, Brodsky JL, Brumell JH, Brunk UT, Bursch W, Camougrand N, Cebollero E, Cecconi F, Chen Y, Chin LS, Choi A, Chu CT, Chung J, Clarke PG, Clark RS, Clarke SG, Clavé C, Cleveland JL, Codogno P, Colombo MI, Coto-Montes A, Cregg JM, Cuervo AM, Debnath J, Demarchi F, Dennis PB, Dennis PA, Deretic V, Devenish RJ, Di Sano F, Dice JF, Difiglia M, Dinesh-Kumar S, Distelhorst CW, Djavaheri-Mergny M, Dorsey FC, Dröge W, Dron M, Dunn WA, Duszenko M, Eissa NT, Elazar Z, Esclatine A, Eskelinen EL, Fésüs L, Finley KD, Fuentes JM, Fueyo J, Fujisaki K, Galliot B, Gao FB, Gewirtz DA, Gibson SB, Gohla A, Goldberg AL, Gonzalez R, González-Estévez C, Gorski S, Gottlieb RA, Häussinger D, He YW, Heidenreich K, Hill JA, Høyer-Hansen M, Hu X, Huang WP, Iwasaki A, Jäättelä M, Jackson WT, Jiang X, Jin S, Johansen T, Jung JU, Kadowaki M, Kang C, Kelekar A, Kessel DH, Kiel JA, Kim HP, Kimchi A, Kinsella TJ, Kiselyov K, Kitamoto K, Knecht E, Komatsu M, Kominami E, Kondo S, Kovács AL, Kroemer G, Kuan CY, Kumar R, Kundu M, Landry J, Laporte M, Le W, Lei HY, Lenardo MJ, Levine B, Lieberman A, Lim KL, Lin FC, Liou W, Liu LF, Lopez-Berestein G, López-Otín C, Lu B, Macleod KF, Malorni W, Martinet W, Matsuoka K, Mautner J, Meijer AJ, Meléndez A, Michels P, Miotto G, Mistiaen WP, Mizushima N, Mograbi B, Monastyrska I, Moore MN, Moreira PI, Moriyasu Y, Motyl T, Münz C, Murphy LO, Naqvi NI, Neufeld TP, Nishino I, Nixon RA, Noda T, Nürnberg B, Ogawa M, Oleinick NL, Olsen LJ, Ozpolat B, Paglin S, Palmer GE, Papassideri I, Parkes M, Perlmutter DH, Perry G, Piacentini M, Pinkas-Kramarski R, Prescott M, Proikas-Cezanne T, Raben N, Rami A, Reggiori F, Rohrer B, Rubinsztein DC, Ryan KM, Sadoshima J, Sakagami H, Sakai Y, Sandri M, Sasakawa C, Sass M, Schneider C, Seglen PO, Seleverstov O, Settleman J, Shacka JJ, Shapiro Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4(2):151-75, 2008. PMID: 18188003.
31. Ng AW, Wasan KM, Lopez-Berestein G Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci 6(1):67-83, 2003. PMID: 12753730.
32. Tari AM, Lopez-Berestein G Cellular uptake of antisense oligonucleotides. Curr Opin Investig Drugs 2(10):1450-3, 2001. PMID: 11890364.
33. Ozpolat B, Lopez-Berestein G, Mehta K ATRA(ouble) in the treatment of acute promyelocytic leukemia. J Biol Regul Homeost Agents 15(2):107-22, 2001. PMID: 11501968.
34. Wasan KM, Lopez-Berestein G Diversity of lipid-based polyene formulations and their behavior in biological systems. Eur J Clin Microbiol Infect Dis 16(1):81-92, 1997. PMID: 9063678.
35. Wasan KM, Lopez-Berestein G Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. Clin Infect Dis 23(5):1126-38, 1996. PMID: 8922813.
36. Wasan KM, Lopez-Berestein G Modification of amphotericin B's therapeutic index by increasing its association with serum high-density lipoproteins. Ann N Y Acad Sci 730:93-106, 1994. PMID: 8080218.
37. Wasan KM, Lopez-Berestein G The interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu. J Drug Target 2(5):373-80, 1994. PMID: 7704481.
38. Wasan KM, Lopez-Berestein G The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers. Arch Med Res 24(4):395-401, 1993. PMID: 8118164.
39. Levine SJ, Walsh TJ, Martinez A, Eichacker PQ, Lopez-Berestein G, Natanson C Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med 114(8):664-6, 1991. PMID: 2003714.
40. Lopez-Berestein G Liposomes in infectious diseases: present and future. Curr Clin Top Infect Dis 10:241-53, 1989. PMID: 2679695.
41. Lopez-Berestein G, Bodey GP, Frankel LS, Mehta K Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol 5(2):310-7, 1987. PMID: 3806172.
42. Anaissie E, Kantarjian H, Jones P, Barlogie B, Luna M, Lopez-Berestein G, Bodey GP, Fusarium A newly recognized fungal pathogen in immunosuppressed patients. Cancer 57(11):2141-5, 1986. PMID: 3457624.
43. Shirkhoda A, Lopez-Berestein G, Holbert JM, Luna MA Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B. Radiology 159(2):349-53, 1986. PMID: 3961167.
44. Kalter S, Lopez-Berestein G Acquired immune deficiency syndrome in a patient with prior sarcoidosis: case report with monocyte function studies. Tex Med 81(9):44-6, 1985. PMID: 4049293.
45. Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta R, Luna M, Hersh EM, Reuben J, Juliano RL, Bodey GP Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 151(4):704-10, 1985. PMID: 3973417.
46. Lopez-Berestein G, Kilbourn R Mononuclear phagocyte system cytotoxins: a review. Nat Immun Cell Growth Regul 4(2):78-89, 1985. PMID: 3894941.

Editorials

1. Lopez-Berestein G. The postential of drug-carrying Immunoliposomes as anticancer agents. Clin Can Res 8:955-956, 2002.

Book Chapters

1. Oncul, S, Amero, P, Rodriguez-Aguayo, C, Sood, AK, Calin, GA, Lopez Berestein, G. RNA delivery for cancer gene therapy, 375-424, 2022.
2. Mangala, LS, Rodriguez-Aguayo, C, Bayraktar, E, Jennings, NB, Lopez Berestein, G, Sood, AK. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models, 157-168, 2021.
3. Armaiz-Pena GN, Ozpolat B, Sood A, Lopez-Berestein G. Nanomedicine-based use of siRNA in Cancer. In: Nanomedicine and Cancer. Science Publishers, 2012.
4. Alpay SN, Ozpolat B. Delivering siRNA using nanoparticles to the central nervous system. In: Nanomedicine and the Nervous System. Science Publishers, 2012.
5. Akar U, Ozpolat B, Verma A, Lopez-Berestein G, Mehta K. Tissue transglutaminase: A novel regulator of autophagic cell death in cancer cells. In: Research Advances in Cancer, 2007.
6. Lopez-Berestein G. Mycoses in AIDS Patients. In: Topics in Mycology. First Edition. Plenum Press, 2007.
7. Ozpolat B, Akar U, Mehta K, Lopez-Berestein G. PKC and Tissue Transglutaminase are Novel Inhibitors of Autophagy in Pancreatic Cancer Cells. In: Research Advances in Cancer. First Edition, 2007.
8. Ozpolat B, Lopez-Berestein G. All-trans-Retinoic Acid and Treatment of Acute Promyelocytic Leukemia. In: Vitamin A: New Research. Chapter I. Nova Science Publishers, 1-23, 2007.
9. Wasan KM, Ng AWK, Lopez-Berestein G. Development and Current Use of Liposomal Polyene Antibiotics. In: Methods in Enzymology. First Edition. Academic Press, 2007.
10. Siwak D, Tari A, Lopez-Berestein G. Liposomal Antisense Oligonucleotides for Cancer Therapy. In: Methods in Enzymology: “Liposomes”. Chapter 15. Academic Press, 2003.
11. Lopez-Berestein G. Macrophages in Cell Biology. In: Cell Biology Reviews. Cell Biology Reviews, In Press, 2000.
12. Tari A M Lopez-Berestein G. Antisense Therapy of cancer. In: Progress in Cancer. Progress in Cancer, 31-37, 1999.
13. G Nystatin WTLL. Nystatin. In: Antimicrobial Therapy and Vaccines / Eds. Yu, Merigan and Barrier. Williams and Wilkins, 1185-1191, 1998.
14. Mehta K, Estey E, Lopez-Berestein G. Liposomal-Retinoids. In: Targeting of Drugs 6: Strategies for Stealth Therapeutic Systems / Ed. Gregoriadis. Plenum Press, 87-94, 1998.
15. Wasan K Lopez-Berestein G. The history of Liposomal Amphotericin B / D. Papahadjopoulos (ed.). In: Liposomes Technology and Research, 1997.
16. Lopez-Berestein G, Mehta K, Mehta R, Juliano R, Hopfer R. Liposomes in antimicrobial therapy. In: Targeting of Drugs with Synthetic Systems. Targeting of Drugs with Synthetic Systems, 211-228, 1996.
17. Tari A M, Neamati N, Andreeff M, Lopez-Berestein G. Liposomal delivery of oligonucleotides in Chronic Myelogenous Leukemia. In: Targeting of Drugs 5, Strategies for oligonucleotide and gene delivery in therapy / NATO ASI Series, Series A: Life Sciences. Plenum Press, 163-168, 1996.
18. Wasan KM, Lopez-Berestein G. The use of liposomes in the treatment infectious diseases in cancer patients. In: Liposomes in Cancer Therapy / S. Sugarman and R. Perez-Soler (eds.),. Liposomes in Cancer Therapy, 41-61, 1995.
19. Wasan K Lopez-Berestein G. Behavior of Liposomal Amphotericin B in the biological milieu. In: New York Acad. Sci. New York Acad. Sci, 93-106, 1994.
20. Wasan K Lopez-Berestein G. The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of liposomal amphotericin B. In: Archives of Medical Research. Archives of Medical Research, 1-7, 1993.
21. Lopez-Berestein G. Liposomes in infectious diseases: Present and future. In: Current Clinical Topics in Infectious Diseases. Blackwell Sci, 241-253, 1992.
22. Lopez-Berestein G Rosenblum M. Treatment and pharmacokinetics of liposomal-Amphotericin B in patients with systemic fungal infections. In: Combination Therapies. Plenum Press, 105-112, 1992.
23. Mehta R T Lopez-Berestein G. Effect of liposomes encapsulation on toxicity and antifungal activity of polyene antibiotics. In: Liposomes in the Treatment of Infectious Diseases and Cancer. Liposomes in the Treatment of Infectious Diseases and Cancer, 263-274, 1989.
24. Lopez-Berestein G. Treatment of systemic fungal infections with liposomal amphotericin. In: Liposomes in the Treatment of Infectious Diseases and Cancer. Liposomes in the Treatment of Infectious Diseases and Cancer, 317-328, 1989.
25. Perez-Soler R, Lopez-Berestein G, Khokhar A R. Design and development of liposomes-dependent antitumor agents. In: Liposomes in the Treatment of Infectious Diseases and Cancer. Liposomes in the Treatment of Infectious Diseases and Cancer, 59-70, 1989.
26. Lopez-Berestein G. Liposomal-amphotericin B the treatment of systemic mycoses in patients with cancer. In: Diagnosis and Therapy of Systemic Fungal Infections. Raven Press, 150-166, 1989.
27. Lopez-Berestein G Fidler I J. Liposomes in the Therapy of Infectious Diseases and Cancer. In: UCLA Symposia on Molecular and Cellular Biology / New Series / Volume 89. Alan R. Liss, Inc, 1989.
28. Perez-Soler R, Khokhar A, Lopez-Berestein G. Liposomes as carriers of antineoplastic drugs. In: Liposomes as Drug Carriers: Trends and Progress. Liposomes as Drug Carriers: Trends and Progress, 401-417, 1988.
29. Lopez-Berestein G. Drug Carriers for Polyene Antibiotics. In: Antifungal Drugs. Antifungal Drugs, 590-597, 1988.
30. Lopez-Berestein G Perez-Soler R. Prospects of liposomes as drug carriers. In: Anticarcinogenesis and Radiation Protection. Anticarcinogenesis and Radiation Protection, 441-450, 1988.
31. Lopez-Berestein G. Liposomal-amphotericin B in antimicrobial therapy. In: Liposomes as Drug Carriers: Trends and Progress. Liposomes as Drug Carriers: Trends and Progress, 345-352, 1988.
32. Lopez-Berestein G, Juliano R L. Liposomes as carriers of antifungal agents. In: Liposomes, From Biophysics to Therapeutics. Liposomes, From Biophysics to Therapeutics, 253-276, 1987.
33. Rodriguez-Aguayo C, Chavez-Reyes A, Lopez-Berestein G, Sood AK. Advanced Delivery and Therapeutic Applications of RNAi. In: RNAi in Cancer Therapy. John Wiley & Sons. Inc.
34. Ozpolat B, Akar U, Dalby K, Lopez-Berestein G. Induction of Autophagic Cell Death by Polyphenolic Compounds in Cancer: A Novel Strategy to Treat Cancer. In: Cell Death Mechanisms in Cancer. Springer.
35. Tekedereli I, Lopez-Berestein G, Ozpolat B. Induction of Autophagic Cell Death by Targeting Bcl-2 as A Novel Theraputic Strategy in Breast Cancer. In: Breast Cancer. Open Access.

Books (edited and written)

1. Lopez-Berestein G, Fidler IJ. Liposomes in the Treatment of Infectious Diseases and Cancer. Alan R. Liss, 2006.
2. Lopez-Berestein G. Cell Biology Reviews, 2000.
3. Lopez-Berestein G, Klostergaard J. Mononuclear phagocytes in cell biology. CRC Press, 1992.
4. Lopez-Berestein G, Fidler IJ. Liposomes in the Treatment of Infectious Diseases and Cancer, 1989.

Letters to the Editor

1. Chakraborty, D, Gutierrez-Chakraborty, E, Rodriguez-Aguayo, C, Başağaoğlu, H, Lopez Berestein, G, Amero, P. Discovering genetic biomarkers for targeted cancer therapeutics with eXplainable Artificial Intelligence. Cancer Communications 44: 584-588, 2024.